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Abstract 
 
Background and purpose 
Health-related quality of life is an important issue in the treatment of breast cancer and 
health-state utilities are essential for cost-utility analysis. This paper identifies and 
summarizes published utilities for common health-related quality of life outcomes for 
breast cancer, considers the impact of variation in study designs used and pools utilities 
for some breast cancer health states. 
 
Data sources and study selection 
13 databases were searched using key words relating to breast cancer and utility 
measurement. Articles were included if specified empirical methods for deriving utility 
values were used and details of the method, including number of respondents, were 
given. Articles were excluded if values were based on expert opinion or were not 
unique. 
 
Data extraction and synthesis 
The authors identified 49 articles which met their inclusion criteria providing 476 
unique utilities for breast cancer health states. Where possible mean utility estimates 
were pooled using ordinary least squares with utilities clustered within study group and 
weighted by both number of respondents and inverse of the variance of each utility. 
Regressions included controls for disease state, utility assessment method and other 
features of study design. 
 
Results 
Utility values found in the review are summarized for six categories 1) screening related 
states, 2) preventative states, 3) adverse events in breast cancer and its treatment, 4) 
non-specific breast cancer, 5) metastatic breast cancer states and 6) early breast cancer 
states. Pooled utility values for the latter two categories are estimated, showing base 
state utility values of between 0.668 and 0.782 for early breast cancer and 0.721 and 
0.806 metastatic breast cancer depending upon which model is used. Utilities were 
found to vary significantly by valuation method, and who conducted the valuation.  
 
Conclusions 
A large number of utility values for breast cancer are available in the literature, the 
states for which these refer to are often complex making pooling of values problematic.  
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The impact upon quality of life and length of life are both important to the assessment 
of treatments for breast cancer. These outcomes can be combined using the health-
related quality of life measure of a QALY (quality adjusted life year). QALYs may be 
thought of as a ‘utility’ score since they represents people’s preferences towards a 
particular health state, where 0 represents dead and 1 represents full health. Being able 
to locate any health state on a 0 to 1 scale allows an estimation of the number of 
QALYs a treatment brings, and subsequently, a comparison of the cost per QALY 
benefit across different treatments. The cost per QALY of competing treatments can be 
a useful input into medical decision making and priority setting (1). 
 
Cost per QALY for breast cancer treatments may be derived from primary research, or 
from modelling interventions at different disease stages. Where modelling is conducted, 
modellers require a ‘utility’ value for each possible health state e.g. newly diagnosed 
breast cancer, currently undergoing chemotherapy and experiencing some toxicity from 
treatment. This allows them to map the profile of hypothetical patients as they pass 
through different scenarios and understand the QALYs gained from alternative 
treatments. 
 
There are numerous studies which have investigated the utility values associated with 
breast cancer, unfortunately, they show considerable variation in results. For example, 
values for metastatic breast cancer (MBC) range from -0.52 to 0.882. What explains this 
variation? Firstly, there are a number of different health states which an individual with 
MBC may experience relating to different treatment regimes, different responses to 
treatment and different possible side-effects of treatment. Secondly, there are different 
methods for generating utility scores, which can generate different values for the exact 
same health state.  
 
This study aims to systematically review health state utility values (HSUVs) for breast 
cancer (early and metastatic) in order to identify all breast cancer HSUVs in the current 
literature. It then seeks to provide a pooled estimate of HSUVs for each identifiable 
health state within breast cancer. It also seeks to understand the impact of different 
methodological techniques on the estimates of utility scores for breast cancer. This will 
generate a list of HSUVs that can be used in future economic evaluations, and offer 
greater understanding of how representative individual utility estimates are for breast 
cancer states. 
 
 
METHODS 
 
Methods for deriving a utility value 
 
There are a number of methods for deriving HSUVs for economic evaluation (2), either 
by expert opinion (authors or expert panels) or empirically. This review is only 
concerned with the latter, of which there are four approaches: 
 
Firstly, preferences may be elicited about specially constructed vignettes or scenarios 
which describe a particular health state. This is done in three main ways. A) Using a 
visual analogue scale (VAS) in which the respondent marks the health state on a line 
anchored from 0 (usually marked as worst imaginable health or dead) to 1 (usually 
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marked as full health, best health imaginable or best health imaginable for age). B)  
Using standard gamble (SG) questions which ask respondents to choose between a 
specified health state for the rest of their lives or a gamble between full health and dead 
(or some other better and worse outcome than the state being valued). C) Using a time 
trade-off (TTO) question which asks respondents to choose between a specified health 
state for a certain period of time representing their future life expectancy and full health 
(or some other better health state) for a reduced period of time. Hence respondents trade 
length of life for a health improvement. There are a number of possible groups who 
could undertake this valuation: patients, those at risk of developing the condition, 
members of the public (with or without a similar profile to the typical patient), or 
clinical staff. 
 
Secondly, preferences of the patient population towards their own current health may be 
measured directly, typically also using VAS, SG or TTO. 
 
Thirdly, a health state may be described using an existing generic multi-attribute health 
state descriptive system for which a set of values obtained from the preferences of a 
general population sample exists, such as the EQ-5D (3), SF-6D (4), or the HUI3 (5).  
 
Lastly, condition specific or generic health related quality of life (HRQoL) instruments 
which either have general population preferences which place them on a 0 (dead) to 
1(full health) scale or may be mapped onto existing utility scales (e.g. a value from the 
disease specific instrument may be mapped onto a value from the EQ-5D). 
 
Utility values from generic instruments like the EQ-5D, HUI2 and HUI3, and those 
derived from direct TTO, SG and VAS are all intended to give the Q part of a QALY. 
These diverse methods are unlikely to generate consistent responses for the utility level 
of different health states, and as shall be seen later, choice of valuation method makes a 
considerable difference to the utility value associated with particular breast cancer 
related states.  
 
Pre-scored multi-attribute health state descriptive systems found in this review include 
the EQ-5D (3), the HUI (5) and the HALex (6). 
 
The EQ-5D, for example, classifies individual health states according to five 
dimensions: (1) mobility, (2) self care, (3) usual activity, (4) pain or discomfort, and (5) 
anxiety or depression. Each dimension is divided into three hierarchical levels of 
dysfunction, giving 245 distinct health states. The social tariff gives valuations for each 
health state. The social tariff, or scoring algorithm, for the UK is based on TTO 
preferences of a large random sample of the UK public (3). EuroQol values are 
anchored by ‘1’ representing full health and ‘0’ representing the state ‘dead’ with states 
‘worse than death’ bounded by ‘-1’. This set of utility weights is referred to 
subsequently as the ‘UK tariff’. The EQ-5D is often administered with a VAS (or 
feeling thermometer) requiring a direct valuation of the individual’s health on a scale 
from worst health imaginable to best imaginable. 
 
The Health Utilities Index (HUI) has two versions, the HUI2 and the HUI3 (5). The 
HUI3, for example, defines 960,000 health states using eight attributes (vision, hearing, 
speech, ambulation, dexterity, emotion, cognition and pain). HUI states have been 
valued by parents of school children from Hamilton, Canada (n=256), using SG 
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estimated from transformed VAS scores (7), using multi-attribute utility theory. Scores 
are bounded by 1 and 0.03 for the HUI2 and by 1 and -0.36 for the HUI3.  
 
Health and Activity Limitation Index (HALex) (6) is drawn from the Healthy People 
2000 survey (8), and the National Health Interview Survey which contains data on two 
direct measures of health: perceived health (‘Would you say your health in general is 
excellent, very good, good, fair or poor?) and activity limitation. Each person is 
classified into one of six categories based on age and the ability to perform a major 
activity giving 30 possible health states, with death assigned the 31st and worst state. A 
multiplicative, multi-attribute model was used to assign scores for these health states. 
The healthiest state is assigned a score of 1.0 and the dead state a score of 0. The value 
of the most dysfunctional living state, ‘limited in activities of daily living and in poor 
perceived health’, is assigned a value of 0.10, drawn from the HUI-1. This measure is 
not based on preferences of a representative sample of the public, therefore does not 
strictly meet the inclusion criteria, however, HSUVs using the HALex are included 
because they are available at the population level in the US and consequently provide an 
interesting comparison. 
 
The National Institute for Health and Clinical Excellence (NICE) makes 
recommendations for UK public funding of treatments across different technologies and 
disease areas. To facilitate a consistent approach to appraisals across different areas 
NICE has defined a ‘reference case’ that specifies what it considers the most 
appropriate methods for assessing health benefits for its purposes and those which are 
consistent with an NHS objective of maximising health gain from limited resources. 
The reference case specifies that HSUVs should be derived from standardised and 
validated generic instruments which use a choice based method (either TTO or SG) and 
take preferences from the general public (1). Values derived using the third method 
above are therefore of additional importance in the UK context. 
 
 
Literature search and data retrieval 
 
A systematic review of HSUVs for conditions relating to breast cancer was undertaken. 
Published and unpublished work reporting HSUVs in male and female adults with 
conditions relating to breast cancer were identified. In addition to the systematic 
searching of electronic databases, experts were contacted, and reference lists were 
checked. 
 
13 databases were searched using key terms to identify HSUVs in breast cancer1
 
. These 
were MEDLINE, MEDLINE-in progress, MEDLINE other non-index citations, Econlit, 
EMBASE, Cochrane databases (Cochrane Database of Systematic Reviews, Database 
of Abstracts of Reviews of Effectiveness (DARE), Cochrane Central Register of 
Clinical Trials, Technology Assessment (HTA), Economic Evaluation (NHS EED)), 
Science Citation Index, Social Science Citation Index and the Conference Proceedings 
Citation Index - Science.  
                                                 
1 Searched on the 18th March 2009 
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In addition to the databases noted above Google Scholar2, The Center for the Evaluation 
of Value and Risk in Health CEA registry of preference weights3 (1998-2007) and the 
Patient Reported Outcome Measurement (PROM) bibliography4 were also searched5
 
.  
The search terms used were adapted from the strategy adopted in Hind et al.(11). In 
addition to breast cancer terms, the main concepts used to identify HSUVs were: quality 
adjusted life years, healthy year equivalents, quality of well being, standard gamble, 
time trade-off, discrete choice experiment, health state utility, preferences and values. 
The detailed search terms are available from the authors (as an example, the terms used 
for the MEDLINE search are shown in Appendix A). This very broad strategy was 
designed to minimize the risk of missing relevant papers. 
 
Inclusion criteria for the review were: concerned with an adult population with breast 
cancer; contained at least one original, unique utility value, used one of the four 
empirical methods listed above to derive HSUVs and gave details of both the elicitation 
technique and the respondents, and available in English or available translation. Studies 
were therefore excluded if they based utility values on judgement, either of a non-
specified number of clinical staff, or on judgement of the author. 
 
Study selection was conducted in a systematic sifting process over three stages: title, 
abstract and full text. At each stage studies were rejected that definitely did not meet the 
inclusion criteria. The data extracted from those studies that met the inclusion criteria 
(shown in Appendix B: Table 1) includes: 
 
1) Authors, year and country from which the data is taken 
2) Mean and/or median utility weight and health state or disease category to which 
it refers  
3) Standard deviation or confidence interval if reported, or range/IQR if medians 
4) The assessment method (i.e. SG, TTO, VAS, EQ-5D etc.)  
5) The lower and upper bound of the scale (i.e., death or worst possible health; 
perfect health, or normal health etc.).  
6) The respondents from whom utilities were elicited (i.e. patients, members of the 
community, clinicians) 
7) Whether valuations are of the patients’ own health or of a vignette   
8) The number of respondents  
9) The mean age of respondents 
 
In order to assess whether the study results are representative of the study sample 
additional information was extracted on respondent selection and recruitment, inclusion 
and exclusion criteria, response rates and any possible problems with the study.  
                                                 
2 Searched on 1st April 2009, using the phrases “health state utilities” and “breast cancer” and at least one 
of HUI, TTO, SG, EQ-5D, SF-6D, SF-12, VAS, QWB, HALex or Euroqol, from 2000, searching in the 
subject areas of Medicine, Pharmacology and Veterinary Science and Social Science, Arts and 
Humanities. 
3 https://research.tufts-nemc.org/cear/default.aspx 
4 http://phi.uhce.ox.ac.uk/perl/phig/phidb_search.pl 
5 Using the key word ‘cancer’ and instrument type ‘utilities’ with the addition of ‘breast’ as free text. The 
CEA found 58 papers, all but 2 of which were identified by the initial search (Stevenson et al. (9) and 
Sonnenberg et al. (10)), neither of which met the inclusion criteria. The PROM bibliography found 58 
papers, all of which had previously been identified. The Google Scholar search identified 306 unique 
papers, of which 23 had been identified by the original search, 266 were excluded at the title stage, 10 
were excluded from abstracts and 7 papers were read, none of which met the inclusion criteria.  
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Where contact details could be attained, contact with the authors was made to attempt to 
get standard deviations and means if these were not reported in papers and full study 
details where only abstracts were available6
 
.  
 
Data synthesis 
 
HSUVs found in the review fall into six categories 1) screening related states, 2) 
preventative states, 3) adverse events in breast cancer and its treatment, 4) non-specific 
breast cancer, 5) early breast cancer states and 6) metastatic breast cancer states. 
 
Where there are a sufficient number of values within a category meta analysis is used to 
provide breast cancer utilities based on combining all available evidence. Meta-
regression uses the measure of utility as the dependent variable with study 
characteristics as independent variables, hence allows pooling of HSUVs while 
considering variation in study methods (e.g. respondent types, valuation method used 
etc.). This offers increased understanding of the impact of study design on HSUVs for 
breast cancer. Few meta-analysis for HSUVs have been conducted; examples include 
McLernon et al.(12) for liver disease, Bremner et al.(13) for prostate cancer, Tengs and 
Lin(14) for HIV/AIDS and Tengs and Lin(15) for stroke. No review or meta analysis 
has been conducted for HSUVs in breast cancer. 
 
The method used here is simple, pooled, ordinary least squares. Values from studies 
where the mean estimate is given with a smaller standard deviation (hence the study is 
more certain about the true utility value) are given more weight than those with a larger 
standard deviation. Since not all studies provide a standard deviation, HSUVs are also 
weighted by sample size, which should correlate highly with standard deviation. 
 
One problem with the data collected here is that most studies report more than one 
utility value. Often the same individual will provide a number of utility values, either 
using different methods to value the same state, or using the same method at different 
time periods, or the same method for different states. Within study and within person 
values are likely to be more strongly correlated with each other than would be the case 
if each study gave only one value. 
 
This potential correlation between values may result in underestimates of measures of 
uncertainty. This may mean coefficients appearing to be significant when they are in 
fact not. This potential correlation is addressed in the analysis through clustering at the 
within study group level, which increases the standard errors. Analysis is conducted 
using Stata 10.  
 
RESULTS 
 
The electronic search identified 1,481 unique papers and 20 papers were identified 
through other means. 1,162 were excluded at the title stage, and 96 from abstracts.  
                                                 
6 We would like to take this opportunity to thank a number of people who have kindly provided help with 
this study: Ruth Brown, George Dranitsaris, Diane Fairclough, Duska Franic, Jane Hall, Robert Launois, 
Lucio Liberato, Sue-Anne Mclachlan, Simon Pickard, Rob Simons, Sonja Sorensen, W. Warren Suh, 
Jung-Der Wang, Sue Ward and Eve Wittenberg  
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Of the 243 identified as potentially relevant 40 papers were excluded because they did 
not contain breast cancer HSUVs and 119 papers were excluded because they did not 
contain original HSUVs. A further 22 were excluded because, although containing 
original HSUVs, they did not meet the inclusion criteria (mostly utility values were 
estimated by clinicians in an ad hoc manner) (see Appendix B: Table B.2). A further 9 
included original HSUVs but did not present these in a manner in which they could be 
extracted for this review (see Appendix B: Table B.3), and 4 were excluded because 
they contained only drug-specific valuations. A total of 49 papers were therefore 
included within the review (see Appendix B: Table B.1). Each of the 49 papers 
contributed between 1 and 36 HSUVs. 
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Figure 1: Flow diagram showing a summary of study selection and exclusion 
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identified from the electronic 
search: 
N = 1,481 
Papers rejected at the title stage 
N=1,162 
 
Papers rejected at the abstract stage:  
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Total full papers screened:  
 
N = 243 
 
Full papers excluded: 
 
Those without breast cancer HSUVs 
N = 40 
 
Those using HSUV but not original 
data (mostly cost-utility, cost 
effectiveness and Q-TWIST studies, 
some reviews) N=119 
 
 
 
Total full papers accepted by 
sifting: 
 
N = 84 
 
 
 
 
 
Potentially relevant papers 
identified through other means: 
N = 20 
Total papers included into the 
review:  
 
N = 49 
Full papers excluded:  
 
Those with HSUVs but not included 
due to unsuitable vignette or anchors, 
lack of sample size and repetition N= 
22 (see table B:2) 
 
Those with drug-specific HSUVs N= 
4 (see table B:3) 
 
Those without accessible HSUV due 
to presentation N= 9 (see table B:4) 
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The HSUVs identified for the first four categories (screening related states, preventative 
states, adverse events in breast cancer and its treatment, and non-specific breast cancer) 
are not suitable for meta-regression because an insufficient number of utility values 
were identified for each category. These are therefore presented and briefly discussed 
below. 
 
HSUVs for breast cancer screening related states 
Screening states are reported by six studies(16-21), of which Rijnsburger et al.(21) 
interviews women as they progress through a screening program and the remaining five 
studies derive values for hypothetical states described as vignettes.  
 
Screening attendance is given in four studies, all of which use a VAS scale. HSUVs 
range from a mean of 0.790 from patients on the day of screening (anchored at worst-
best health)(21), a mean of 0.804 from women in a surveillance program (anchored at 
dead-full health)(16), to a mean of 0.92 for the week surrounding screening from a 
community sample (anchored at worst-best health)(17), to a median of 0.99 from 
clinicians(18). Whilst it would appear that women in surveillance programmes rate the 
screening experience less favourably than others, the lower utility values found by 
Rijnsburger et al.(21) are not dissimilar to values for the same women 2 months prior to 
screening (0.819) and 1-4 weeks post screening (0.807), suggesting the need for a 
control group from which to derive a utility decrement of the screening procedure. One 
study gives a value of 0.553 (VAS dead-perfect health) for a diagnostic mammography 
(16), which although surprisingly low, may reflect the anxiety and absorbing nature of 
periods of uncertainty. 
 
HSUVs for post screening outcomes are shown in Table 1; however, the time scale to 
which these refer to is not clear and results are not always in line with expectations. For 
example, Johnston et al.(20) found little difference in utility values based on community 
preferences from true positives and false positives.  
 
Table 1: Mean utility values screening states 
 True 
negative 
False 
negative 
True 
positive 
False 
positive 
Bonomi et al.(16):VAS (death-perfect) 
(n=137 women in screening programme) 
0.891 0.485 0.457 0.810 
Gerard et al.(19):EQ-5D (n=440 community 
women) 
0.94 0.45 0.48 0.79 
Johnston et al.(20) :TTO (n=440 community 
women) 
0.91 0.66 0.66 0.66 
Johnston et al.(20):VAS (death-best) (n=440 
community women) 
0.92 0.60 0.75 0.67 
De Koning et al.(18): VAS (worst-best) 
(n=27 clinicians) 
0.89   0.89 
 
These HSUVs do not give a clear indication of values which could be used in modelling 
for breast cancer screening. Greater insight might be gained through consideration of 
utility loss involved in the screening process for other health conditions.  
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Utility values for preventative breast cancer states 
Two studies report HSUVs for preventative states, such as prophylactic mastectomy and 
chemoprevention(22;23). Grann et al.(23) found HSUVs for prophylactic mastectomy 
ranging from 0.56 to 0.86 with higher values for TTO (using a top anchor of disease 
free) than VAS valuations. Cappelli et al.(22) found considerably lower values for 
double mastectomy and oophorectomy ranging from 0.13 to 0.61 with women with 
breast cancer giving higher valuations than either women with high risk of breast cancer 
or members of the general population. 
 
Grann et al.(23) found values for chemotherapy prevention, estimated by TTO (using a 
top anchor of disease free), ranging from 0.79 to 0.90. Values from Cappelli et al.(22) 
are again lower, the SG values ranging from 0.61 for the general population group to 
0.74 for the breast cancer group. However, the extent to which people are valuing the 
consequences of treatment or the remaining risk of developing breast cancer is unclear.  
 
Sackett and Torrance(24) provide a value for mastectomy caused by injury of 0.63 
which is considerably higher than the value they find for mastectomy due to breast 
cancer at 0.48. However, these values are lower than those found for mastectomy by de 
Haes et al.(17), or the post-surgery own health values reported by Jansen et al.(25;26). 
Consequently, although the TTO responses in Sackett and Torrance are for a duration of 
8 years, their values may unduly reflect the initial post-operation phase. 
 
Utility values for adverse events in breast cancer and its treatment 
Three studies report HSUVs for major adverse events(27-29), including endometrial 
cancer, fractures (hip, spine, wrist), DVT and pulmonary embolism, stroke and 
hysterectomy. Values range from 0.922 for DVT(28) to 0.2 for stroke causing severe 
disability(27). However, these values are not necessarily representative of HSUVs 
found for these states when not caused by breast cancer or its treatment. Whilst these 
conditions may have a different impact upon HRQoL when combined with breast 
cancer, there is minimal evidence upon which to draw such a conclusion. The utility 
values for fracture states are problematic because it is not clear how long after fracture 
the scenarios refer yet it is accepted that utility states post fracture vary over time, the 
most severe states experienced in the immediate post fracture period with recovery rates 
varying by type of fracture (see Peasgood et al. (30). 
 
Utility values for non-specific breast cancer states 
Four studies give HSUVs for a general breast cancer state taken from population level 
surveys. Yabroff et al.(31) used the US Medical Expenditure Panel Survey (MEPS) to 
find a 0.05 utility decrement from breast cancer compared to non-cancer controls using 
the HALex (matched by age, gender and education). Sullivan et al.(32) also used the 
MEPS finding a utility decrement from an adjusted regression model of 0.015 for breast 
cancer using the EQ-5D (controlling for age, comorbidity, gender, race, ethnicity, 
income and education).  
 
Ko et al.(33) used the US National Health Interview Survey (NHIS) and the HALex to 
show improving utility values over time since breast cancer diagnosis from 0.62 during 
the acute phase (<1 year post diagnosis) rising to 0.69 between 1 and 5 years and 0.71 5 
years after diagnosis. Yabroff et al.(34) also used the NHIS and the HALex and found 
values of 0.78 for the first year after breast cancer diagnosis, 0.81 for the continuing 
stage and 0.64 for the last year of life, compared to controls at 0.85, 0.85 and 0.73, 
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respectively. These findings emphasise the important role time scale plays in the 
HRQoL of breast cancer patients. 
 
Three studies took HSUVs from breast cancer patients attending hospital for treatment. 
Stratmann-Schoene(35) identified women who had received surgery for breast cancer 
(the current stage of their cancer is unclear) and reported utility values of 0.724 based 
on VAS (worst-best health), and 0.506 when using a model which maps the SF-12 onto 
VAS scores. Isogai et al.(36) found a value of 0.80 using the EQ-5D on 151 breast 
cancer patients (0.1 to 25 years since diagnosis). Shih et al.(37) found a utility value of 
0.81 for 59 breast cancer patients in China using the SF-6D.  
 
Utility values for early and metastatic breast cancer states 
The review identified 117 useable HSUVs relevant to metastatic breast cancer (MBC) 
states from 20 studies: Bonomi et al.(16) (1 value), Cykert et al.(27) (1 value), De Haes 
et al.(17) (4 values) De Koning et al.(18) (2 values), Grann et al.(38) (1 value) Grann et 
al.(23) (8 values), Hauser et al.(39) (16 values), Hurny et al.(40) (5 values), Hutton et 
al.(41) (8 values), Launois et al.(42) (24 values), Lidgren et al.(43) (6 values), Lloyd et 
al.(44) (9 values), Mansel et al.(28) (2 values), McLachlan et al.(45) (1 value), Milne et 
al.(46) (12 values), Pickard et al.(37) (1 value), Schleinitz et al.(47) (2 values), Simons 
et al.(48) (9 values), Sorenson et al.(29) (US values: 2 values) and Walker et al.(49) (2 
values)7
 
. 
The review also identified 230 useable HSUVs for early breast cancer (EBC) states 
from 29 studies: Bernhard et al.(56) (3 values), Bernhard et al.(57) (3 values), Bonomi 
et al.(16) (7 values), Cappelli et al.(22) (12 values), Conner-Spady et al.(58) (14 
values), Cykert et al.(27) (1 value), De Haes et al.(17) (8 values), De Koning et al.(18) 
(4 values), Gordon et al. (59) (3 values), Grann et al.(38) (1 value), Grann et al.(23) (9 
values), Hayman et al.(60) (10 values), Hayman et al.(61) (16 values), Jansen et al.(26) 
(6 values), Jansen et al.(25) (25 values), Jansen et al.(62) (21 values), Jansen et al.(63) 
(8 values), Kimman et al.(64) (20 values), Lidgren et al.(43) (16 values), Lovrics et 
al.(65) (8 values), Mansel et al.(28) (3 values), Namjoshi et al.(66) (4 values), Polsky et 
al.(67) (4 values), Prescott et al.(68) (8 values), Sackett and Torrance(24) (1 value), 
Schleinitz et al.(47) (6 values), Sorenson et al.(29) (3 values), Walker et al.(49) (5 
values), and Wolowacz et al.(69) (1 value)8
                                                 
7 Papers with values for MBC which are excluded from the regression analysis either because of 
insufficient values within that category (palliative plus surgery (De Haes(17) (1 value)); advanced disease 
treatment (De Koning et al.(18) (1 value))) or because they are repeated within other studies (Brown et 
al.(50) (UK values: 10 values), Brown and Hutton(51) (US values:13 values), Kearney et al.(52) (8 
values) (see table A:2)). Drug specific values from Dranitsaris et al.(53) (8 values), Dranitsaris et al.(54) 
(18 values) and Leung et al.(55) (18 values) are also excluded. EQ-5D New Zealand tariff values from 
Milne et al.(46) (4 values) are excluded because these same states are included using EQ-5D UK tariff 
values. For both MBC and EBC where VAS values are converted into SG or TTO values using a standard 
power transformation only the original VAS values are included. Where study utility values are given 
only in medians, these are transformed to an estimate of the mean based on the relationship between mean 
and median in the other EBC and MBC studies where both are given.   
. 
 
8 Papers with values for EBC which are excluded from the regression analysis are: values from Cappelli 
et al.(22) for breast cancer without treatment (6 values); values for disease free state with no adverse 
events (Mansel et al.(28) and Sorensen et al.(29)); values from Grunberg et al.(70) for non-breast cancer 
specific chemotherapy with and without nausea and vomiting (2 values), those from Gerard et al.(71) (6 
values) and Hall et al.(72) (6 values) because they are difficult to classify (see Table A:2). Drug specific 
values from Sorensen et al.(29) (2 values) and Mansel et al.(28) (2 values) are also excluded. Drug 
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The large number of values identified for MBC and EBC states enables data to be 
synthesised by meta regression and for these two categories to be modelled separately9. 
Study design features which are included as covariates for both MBC and EBC models 
include: mean age of respondents (imputed as deviation from the average mean age of 
respondents where each sample group is given equal weight), method of valuation 
technique (SG (which is used as the reference category), TTO with a top anchor of full 
health and TTO with an alternative top anchor, VAS with the anchors of worst to best 
health10, VAS with the anchors of dead to full health, EQ-5D with the UK tariff, and 
any other methods (e.g. HUI3, HALex)), who is valuing (clinical staff (which is used as 
the reference category), community, patients valuing a hypothetical scenario, patients 
valuing their own health), and whether the valuation method allows states worse than 
dead (the reference category being allowing states worse than dead)11
 
.  
The covariates for the models are drawn from the available data restricted to states 
where at least 3 HSUVs are available. Condition specific states within MBC which are 
included as covariates are: the treatment categories of starting treatment (reference 
category), chemotherapy, hormonal therapy, radiotherapy, and no treatment specified; 
the response categories of response, stable (reference category), terminal, progression 
and no response specified; the side-effect categories of peripheral neuropathy or severe 
neuropathy with or without treatment interruption, oedema with or without treatment 
interruption, febrile neutropenia with or without hospitalisation, sepsis, hypercalcaemia, 
other side-effects, and no side-effects mentioned (reference category). 
 
Condition specific states within EBC which are included as covariates are: the surgery 
treatment options of mastectomy followed by reconstruction, mastectomy only, breast 
conserving surgery (BCS, reference category), surgery which is not specified and no 
surgery or no mention of surgery; the non-surgery treatment options of chemotherapy 
(reference category), chemotherapy with toxicity or nausea and vomiting, radiotherapy, 
hormonal therapy, and no mention of treatment; time scale categories of less than 1 year 
(reference category), over 1 year, and time scale not specified; recurrence options of 
recurrence, no recurrence (reference category) and no mention of recurrence; risk of 
recurrence categories of risk under 15%, risk over 15%, and no mention of risk 
(reference category). 
 
Table 2 shows the results for regressions for EBC, (1) is weighted by the inverse of the 
standard deviation, (2) is weighted by sample size but uses the same observations as (1), 
(3) is weighted by sample size using all available utility values and (4) is weighted by 
sample size but drops the age control to further extend the number of included 
observations. Model (5) includes only the 38 EQ-5D values.  
 
                                                                                                                                               
specific values from Bernhard et al.(57) (18 values) are not included separately, but they are included as 
their combined values.  
9 This is necessary because states within EBC and MBC identified in the papers differ considerably 
requiring different control variables to be used. 
10 VAS values from worst to best health, where they are not recalibrated onto a dead-full health scale are 
not true QALY values. They are included, and controlled for, here in order to expand the sample size. 
11 VAS values from worst to best health, although could be used to value states worst than dead, since 
these values are not recoded to place dead as the bottom anchor they are treated as not allowing states 
worst than dead. 
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As can be seen in Table 2, the EBC models explain mean HSUVs fairly well (adjusted 
R2 of between 0.575 to 0.716), however, there are few consistent significant (p < 0.05) 
findings in terms of the impact of treatment or clinical states. The base state (i.e. the 
constant term, which represents the mean utility value when all covariates are set at 
their reference category) for EBC is between 0.668 and 0.782. Differences in valuation 
methods generate the greatest variation in utility values. The 38 EQ-5D values give a 
base state value of 0.794, with clinical staff valuations giving a higher utility by 0.118 
compared to community valuations. However, the explanatory power of this model is 
weak (adjusted R2 of only 0.304), most likely due to the limited number of observations. 
 
HSUVs are significantly higher for at least 1 year post diagnosis or treatment in model 
(1) once more emphasising the importance of the profile of HRQoL for EBC patients. 
Currently undergoing or having had radiotherapy is significantly positive in all models 
increasing HSUVs by between 0.072 and 0.127. This preference for radiotherapy (in 
contrast to MBC where radiotherapy lowers values) suggests value maybe given to 
perceived reduced risk of recurrence. Higher values for radiotherapy are present for 
patient and clinical staff valuations, but not community-based valuations. Compared to 
BCS only, mastectomy and reconstruction has lower utility, significantly so in model 
(2) (-0.066).  
 
 15 
 
Table 2: EBC regression models, dependent variable mean utility value   
    
Variables (1) (2) (3) (4) (5) 
      
Surgery (ref: BCS)     
Mastectomy & 
reconstruction 
-0.043 -0.066* -0.044 -0.042  
 (0.209) (0.0742) (0.176) (0.360)  
Mastectomy 
only 
0.049 0.016 0.018 0.019  
 (0.171) (0.419) (0.374) (0.485)  
Surgery but not 
specified 
0.107*** 0.109*** 0.019 0.027 0.029 
 (0.0003) (0.0001) (0.526) (0.351) (0.284) 
No surgery 
mentioned 
0.058** 0.017 0.018 0.028 0.001 
 (0.044) (0.552) (0.394) (0.408) (0.989) 
Non surgical treatments (ref: chemotherapy)    
Radiotherapy 0.111*** 0.127*** 0.084** 0.072* -0.027 
 (0.009) (0.001) (0.043) (0.055) (0.485) 
Chemotherapy 
with tox or NV 
  -0.025 -0.060 0.000 
   (0.529) (0.102) () 
Hormonal 
therapy 
0.017 -0.009 -0.050 0.019 -0.020 
 (0.594) (0.922) (0.538) (0.643) (0.576) 
No treatment 
mentioned 
0.053 0.077 0.046 0.054 -0.052 
 (0.182) (0.104) (0.271) (0.140) (0.187) 
      
Time period (ref: under 1 year)    
Over 1 year 0.091** 0.061 0.026 0.045 0.026 
 (0.013) (0.112) (0.375) (0.138) (0.469) 
Time not 
specified 
0.033 0.012 0.014 0.025 0.028 
 (0.196) (0.682) (0.665) (0.244) (0.234) 
      
Recurrence (ref: no recurrence)     
Recurrence -0.015 -0.072 -0.032 -0.011 0.015 
 (0.839) (0.555) (0.761) (0.898) (0.804) 
Recurrence not 
mentioned 
-0.033 -0.038 0.005 -0.028 -0.015 
 (0.457) (0.449) (0.917) (0.455) (0.209) 
      
Risk of recurrence (ref: no risk mentioned)    
Risk under 15% -0.003 -0.051 0.006 0.073  
 (0.956) (0.552) (0.915) (0.223)  
Risk over 15% 0.041 -0.014 0.031 0.076  
 (0.479) (0.893) (0.708) (0.323)  
      
Age (deviation from mean of 53)     
Age difference -0.002 -0.004** -0.002   
 (0.276) (0.0310) (0.139)   
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Whose values (ref: community sample)    
Clinician 0.107* 0.093 0.090 0.168** 0.118** 
 (0.0901) (0.109) (0.107) (0.0299) (0.0290) 
Patients’ own 
health 
0.115** 0.107** 0.168*** 0.251***  
 (0.033) (0.025) (0.0004) (9.35e-08)  
Patients’ 
scenario 
0.054 0.073* 0.049 0.103**  
 (0.304) (0.076) (0.234) (0.048)  
      
States worse than dead (ref: not allowed)    
States worse 
than dead 
allowed 
-0.002 -0.050 -0.069** -0.024  
 (0.943) (0.189) (0.045) (0.378)  
      
Valuation method (ref: SG)     
TTO top anchor 
full health 
-0.025 -0.065 -0.073 -0.092***  
 (0.301) (0.224) (0.104) (0.009)  
TTO top anchor 
not full health 
0.017 -0.056 -0.027 0.057  
 (0.752) (0.387) (0.601) (0.325)  
VAS worst-best -0.095** -0.168** -0.221*** -0.205***  
 (0.0228) (0.0210) (0.00278) (7.54e-05)  
VAS dead-full -0.222*** -0.288*** -0.282*** -0.224***  
 (0.000202) (0.000454) (1.23e-05) (1.42e-06)  
EQ-5D UK -0.095*** -0.103* -0.150*** -0.176***  
 (0.00262) (0.0535) (0.00536) (3.79e-06)  
Other -0.120*** -0.150* -0.179** -0.181***  
 (0.007) (0.054) (0.025) (0.001)  
      
Constant 0.696*** 0.782*** 0.771*** 0.668*** 0.794*** 
 (1.89e-09) (1.28e-07) (1.41e-09) (4.60e-10) (0) 
      
Observations 133 133 188 230 38 
R-squared 0.642 0.716 0.646 0.575 0.304 
Robust p values in parentheses.       
*** p<0.01, ** p<0.05, * p<0.1      
A test for normality of residuals rejects a null of normality (Shapiro-Wilk W test), suggesting potential 
inaccuracies with the hypothesis testing. The removal of 3 observations with the largest residuals restores 
normality of the residuals and does not alter the findings. Consequently, these 3 observations remain 
included. 
 
As with the EBC models, Table 3 shows the results for regressions for MBC, (1) is 
weighted by the inverse of the standard deviation, (2) is weighted by sample size but 
uses the same observations as (1), (3) is weighted by sample size using all available 
utility values and (4) is weighted by sample size but drops the age control. Model 
performance is fairly good with an adjusted R2 ranging from 0.804 to 0.824. 
 
The base state for MBC varies between 0.721 and 0.806. The reason this is higher than 
the base state for EBC may be explained in part by the use of the reference category of 
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‘starting treatment’ rather than ‘chemotherapy’ as used for EBC which according to the 
model reduces values by about 0.14. There are only 8 EQ-5D values for MBC, too few 
to run the model separately. A weighted average of these values gives a utility value of 
0.416, with a large confidence interval (95% CI 0.037 to 0.795) the range in part 
influenced by the inclusion of a value of -0.52 for hypercalcaemia(46). The lower EQ-
5D average compared to the MBC base state also arises due to the fact that the base 
state refers to a stable position, whereas EQ-5D values are drawn from health states 
where disease progression is not specified.  
 
Compared to being at the start of treatment undergoing hormonal therapy lowers utility 
least (not significant), then chemotherapy (-0.127 to -0.149), then radiotherapy (-0.218 
to -0.288). This is an interesting contrast to radiotherapy in EBC models, which may 
arise due to the more severe regime of radiotherapy for MBC. However, there are only 5 
(all community-based) values for MBC with radiotherapy. 
 
As would be expected, compared to being stable, responding to treatment raises utility 
(0.106 to 0.116), and progression and terminal state lowers utility (-0.143 to -0.202 and 
-0.296 to -0.377, respectively). The majority of utility values are of states without a 
specified disease progression. Those without a clear statement of disease progression 
have utility values lower than the stable state (-0.135 to -0.203) which suggests an 
implicit assumption of disease progression. There is a decline in utility values of around 
0.4 to 0.5 as patients move through MBC states suggesting a dramatic loss in quality of 
life with disease progression. However, all values for these categories are drawn from 
hypothetical valuations of the respective scenarios, with no corresponding direct 
evidence from patients.  
 
The impact of side-effects varies slightly between models, the most severe reduction to 
HSUVs is from hypercalcaemia (-0.582 to -0.679). However, these values all come 
from one study(46) and arise due to the low tariff value given to the worst health state 
(33333) on the EQ-5D UK tariff (-0.59). If the EQ-5D New Zealand tariff is used for 
this sample instead hypercalcaemia is valued at -0.05 rather than -0.52. Sepsis lowers 
utility values by -0.249 to -0.284, peripheral and severe neuropathy by up to -0.191, 
oedema and severe oedema by -0.096 to -0.123. The presence of other side-effects are 
non-significant, however, counter-intuitively, febrile neutropenia increases values by up 
to 0.092. As can be seen in Appendix A: Table A.1 the number of utility values for side-
effects are small, hence these results should be interpreted with caution. Information on 
utility values for side-effects may be usefully drawn from similar treatments for 
different cancers (e.g. Nafees et al. (73)). However, a full overview of utility values for 
cancer treatment side-effects would require a different search strategy. 
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Table 3: MBC regression models, dependent variable mean utility value 
 
VARIABLES 1 2 3 4 
     
Treatment type (ref: starting treatment)    
Chemotherapy -0.127*** -0.142*** -0.149*** -0.140*** 
 (0.00359) (0.00632) (0.00208) (0.000691) 
Hormonal therapy -0.014 -0.023 -0.073 -0.033 
 (0.785) (0.683) (0.250) (0.573) 
Radiotherapy -0.218*** -0.231*** -0.288*** -0.238*** 
 (3.32e-05) (0.000154) (2.46e-05) (6.76e-05) 
Treatment not specified -0.160*** -0.196*** -0.177*** -0.183*** 
 (0.00183) (1.19e-06) (0.000159) (2.97e-06) 
     
Response to treatment (ref: stable)    
Response 0.106*** 0.107*** 0.116*** 0.116*** 
 (0.00117) (0.000418) (5.74e-07) (3.75e-07) 
Progression -0.143 -0.190** -0.202*** -0.202*** 
 (0.138) (0.0404) (0.000172) (0.000118) 
Terminal -0.338*** -0.296*** -0.377*** -0.368*** 
 (0.000685) (0.000703) (8.74e-05) (1.46e-05) 
No response specified -0.135* -0.196*** -0.197*** -0.203*** 
 (0.0705) (0.00278) (0.000248) (3.92e-05) 
     
Side-effects (ref: no side-effects mentioned)    
Peripheral neuropathy -0.094* -0.140** -0.182*** -0.191*** 
 (0.0665) (0.0486) (2.57e-05) (5.13e-06) 
Oedema -0.097** -0.123*** -0.089** -0.096** 
 (0.0103) (0.000225) (0.0366) (0.0291) 
Febrile Neutropenia   0.085** 0.092** 
   (0.0481) (0.0288) 
Sepsis -0.284*** -0.249*** -0.257*** -0.259*** 
 (6.36e-06) (0.000279) (1.43e-05) (1.33e-06) 
Hypercalcaemia -0.582*** -0.629*** -0.679*** -0.653*** 
 (0) (3.29e-10) (0) (0) 
Side-effect 0.106 -0.016 0.092 0.095 
 (0.192) (0.898) (0.130) (0.112) 
     
Age (Deviation from the mean of 46)    
Age difference 0.003 0.001 -0.000  
 (0.285) (0.831) (0.946)  
     
Whose values (ref: community)     
Clinician 0.086 0.032 0.032 0.012 
 (0.304) (0.647) (0.627) (0.783) 
Patients valuing own health 0.213*** 0.249*** 0.258*** 0.253*** 
 (0.00378) (0.000209) (0.000197) (3.05e-05) 
Patients valuing a scenario 0.144*** 0.125** 0.139** 0.122** 
 (0.00237) (0.0200) (0.0159) (0.0287) 
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States worse than dead (ref: not allowed)    
States worst than dead allowed 0.007 -0.029 0.042 0.010 
 (0.904) (0.701) (0.450) (0.851) 
     
Valuation method (ref: SG)     
TTO 0.059 0.086 0.095 0.078 
 (0.386) (0.193) (0.168) (0.219) 
TTO top not full health 0.219*** 0.254** 0.232** 0.227*** 
 (0.00621) (0.0217) (0.0120) (0.000547) 
VAS worst-best -0.055 -0.017 -0.097 -0.015 
 (0.571) (0.875) (0.265) (0.807) 
VAS dead-full -0.036 -0.030 -0.026 -0.052 
 (0.270) (0.240) (0.326) (0.136) 
EQ-5DUK -0.086 -0.037 -0.051 -0.062 
 (0.283) (0.625) (0.452) (0.334) 
Constant 0.721*** 0.797*** 0.786*** 0.806*** 
 (1.92e-08) (1.57e-09) (7.32e-11) (0) 
     
Observations 73 73 109 117 
R-squared 0.824 0.823 0.812 0.804 
Robust p values in parentheses       
*** p<0.01, ** p<0.05, * p<0.1       
A test for normality of residuals rejects a null of normality (Shapiro-Wilk W test), suggesting potential 
inaccuracies with the hypothesis testing. The removal of 4 observations with the largest residuals restores 
normality of the residuals and does not alter the findings. Consequently, these 4 observations remain 
included. 
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Method of valuation 
Choice of valuation method impacts strongly upon HSUVs in both the EBC and MBC 
models. The most common methods for values included in the regressions are SG and 
VAS (see Table A.1). The EBC regressions find VAS, EQ-5D and other methods to 
have significantly lower valuations than SG. In the MBC models, VAS values are 
insignificantly lower. In the EBC regressions TTO values, where full health is the top 
anchor, are generally lower than SG, significantly so for the model (4) (-0.092). 
However, in the MBC regressions, TTO values are not significantly different to SG. 
This suggests that whilst valuation method has an important impact upon the values 
attached to breast cancer states, there is no clear systematic relationship between the 
valuation methods that is relevant to all studies.  
 
What is being valued, by whom and when?  
It is often assumed that patients will give a higher value for health states than either 
clinicians or members of the public (14;24;74). In both the EBC and MBC models the 
highest values come from patients valuing their own health (0.107 to 0.251 in EBC 
models and 0.213 to 0.258 in MBC models compared with community valuations). 
MBC patients give hypothetical scenarios significantly higher values than members of 
the public for all models (0.125 to 0.144) but they are only significantly higher in model 
(4) for EBC (0.103). In addition to the distinction between patients and the public, 
important differences in valuation rest also on patients who are valuing their own 
current health versus patient valuations of a hypothetical scenario. There is some 
suggestion from the models that clinicians (nurses and physicians) give slightly higher 
valuations than members of the public but these differences are not very robust, being 
significant only for model 4 and 5 of EBC. As shown in Table A.1, the majority of 
utility values for EBC are derived from patients. In contrast, the majority of values for 
MBC are from non-patients, in part due to ethical concerns of conducting valuation 
exercises with MBC patients. This would suggest that combined utility scores which do 
not account of who has conducted the valuation risk undervaluing MBC states relative 
to EBC states.    
 
The age of respondents may also impact upon valuations. In this data, for MBC models, 
the deviation in mean age of the sample from the average of the sample means is not 
significant. For EBC models, differences in mean age show slightly lower valuations in 
model (2), with each year the sample mean age is above the average sample means 
lowering values by 0.004.12
 
 
Lower and upper bounds 
Within each method the top and bottom anchor states may vary. The bottom anchor may 
be death, worst imaginable health state which is then recalibrated to death or the worst 
imaginable health state. Where the bottom anchor is death without recalibration 
respondents are unable to value states as worse than death. Although the EQ-5D tariffs 
assign some states negative values that are worse than death, in some cases (e.g. 
Lidgren et al. (43)) these are reset to zero. As shown in Table A.1 about a third of the 
values in the regression analysis are drawn from studies that allow values that are worse 
than death. Franic and Pathak(75) explored the impact of allowing states worse than 
                                                 
12 This negative relationship remains if we excluded patients’ valuations of their own health where it 
might be expected that older patients report lower HSUVs due to declining health with age. 
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dead on utility valuations in breast cancer finding that 15% of their sample considered 
cancer recurrence to be worse than dead. This would suggest that not allowing states 
worse than dead by imposing a lower bound of zero onto valuations would raise 
valuations. For MBC values allowing states worse than dead does not result in 
significantly lower values in the regression models. For EBC, allowing states worse 
than dead gives significantly lower values (-0.069) in model (3).  
 
It is assumed here that the top anchors of full health, perfect health, and excellent health 
are a broadly similar state but the top anchor of absence of condition is a considerably 
poorer health state than full or perfect health. For EBC 5 values are derived from 
valuation method using something other than a full health equivalent top anchor. These 
are from Grann et al.(23) who used a TTO with a top anchor of disease free and Grann 
et al.(38) who used a top anchor for TTO of normal health. For MBC 5 values are 
derived from TTO valuations with a top anchor of disease free, also taken from Grann et 
al.(23) and Grann et al.(38). Because the lower top anchor is only used in one method 
for each cancer type, this is included as a variant of TTO. As expected the top anchor of 
disease free or normal health raises utility values. The VAS values using a best-worst 
scale show little systematic difference to the VAS values using a dead-full health scale.  
 
 
DISCUSSION 
 
Limitations of the regression models 
There may be socio-demographic or clinical factors which influence utility values 
which are not controlled for in the regression models since such data is not available for 
all samples. Individual studies show conflicting evidence for the importance of other 
factors (47;60). Similarly, the full diversity of the methods for generating utility values 
can not be modelled, due to insufficient observations. For example, the duration of the 
health state presented to respondents during valuation procedures varies from 3 days to 
the rest of life expectancy. About a third of the values used within the EBC model are 
derived from papers by Jansen and colleagues who use a 6 month time period followed 
by a return to full health (25;26;62). This is expected to raise TTO valuations due to the 
reduced potential for discounting of the full health years, and lower SG valuations 
because the use of full health as the status quo, as opposed to death, which should mean 
that both the health state and risk of death are valued in terms of losses. However, this 
would not explain the higher TTO than SG values found in the MBC models. Hall et 
al.(72) found that duration in a description of a breast cancer health state did not affect 
valuations, suggesting a constant proportional trade-off. However, Franic et al.(76) 
found that when the chemotherapy health state is presented as only 3 days a high 
percentage would not trade in SG. Consequently, values for 3 days are higher than when 
presented as for the rest of life. 
 
Studies with lack of willingness to trade can not include all individual preferences. The 
partial cascading SG used by Hayman et al. (60;77) and the chained SG used by Jansen 
et al.(25;62) result in a smaller sample size for SG valuations compared to TTO and 
VAS. This may introduce some bias into the comparisons between methods since those 
for whom a value is not given are unlikely to be randomly selected. Although not 
included in the meta analysis (see Table B.3), a good example of non-trading in breast 
cancer can be seen in Perez et al.(78) who conducted TTO on 54 MBC patients in New 
Zealand. The questions involved trading days within the forthcoming month, asked 
monthly for 12 months. Of the 54 patients 14 did not trade on any occasion and in most 
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time periods over 2/3rds of respondents did not trade any days. Those facing the 
prospect of imminent death appear reluctant to further limit their remaining time. 
 
For some combinations of health state and study methodology the model can predict 
HSUVs great than 1, yet utility scores are bounded at 1. Consequently, if such values 
are to be used for modelling they require capping at 1. However, where community 
preferences are used this only applies to very few possible combinations treatments and 
outcomes. 
 
Understanding the relationship between valuation methods 
The relationship between the different valuation methods has been explored in detail in 
the past. It is often assumed that rating scales give the lowest values followed by then 
TTO then SG (79). However, some studies find conflicting results with SG giving the 
lowest value then rating scale then TTO (Hornberger et al., 1992). The EBC models 
find SG to give the highest values, then TTO, then VAS, whereas the order in the MBC 
models is TTO, SG, VAS but differences are not significant. 
 
Group level valuations of health states using different methods have been linked to each 
other either by linear relationships (Wolfson et al.(80)) or power relationships (Torrance 
(81)). Some breast cancer studies use a transformation from VAS to SG or TTO 
utilities. For example, De Haes et al.(17) uses a power function of TTO = 1-(1-
VAS)^1.82, where VAS is anchored at worst-best imaginable health. O’Leary et al.(82) 
explored the relationship between valuation methods for cancer patients preferring a 
plateau model (TTO = 1.07 VAS, for VAS < 0.95, TTO = 1.00 VAS, for VAS > 0.95), 
as many respondents who were unwilling to trade-off any time (even in weeks) gave 
low rating scale values. This only had an R2 of 0.29, hence only a relatively small 
proportion of the total variation in TTO utilities is explained by the rating scale. The 
authors note that, “These results underscore the danger of using individual or averaged 
rating scale values as proxies for time trade-off utilities in patients populations and 
suggest that among patients the constructs measured by time trade-off and the rating 
scale are fundamentally different” (O’Leary et al.(82): 136).  
 
The models here suggest that who values the health state is more important than method 
of elicitation. Patients valuing their own health are between 0.107 and 0.25 higher for 
EBC models and 0.21 to 0.26 for MBC models than community members valuing a 
similar hypothetical state. Differences of this magnitude could make a considerable 
impact on cost-utility ratios. As would be expected, utilities from patients valuing their 
own health are more in-line with utility decrements identified through population level 
surveys. 
 
Patient valuations may be better understood if they are placed in the dynamic context of 
their condition and treatment. Valuations from patients for hypothetical scenarios may 
be influenced by their current or past disease state and their current or past treatment 
regime. Hayman et al.(61) suggest that patient valuations may reflect a need to validate 
previous decisions. For example, patients who had been treated with BCS and 
radiotherapy preferred radiotherapy and BCS even when this led to recurrence and 
mastectomy (utility 0.80) compared to BCS alone which also led to recurrence and 
mastectomy (utility 0.75), however, the public valuations placed recurrence and 
mastectomy following BCS alone as higher (utility 0.84) than recurrence and 
mastectomy following BCS and radiotherapy (utility 0.81).  
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SUMMARY 
 
This review identified 49 papers with utility values which were derived from recognised 
methods for the estimation of QALYs. From these, 117 values for MBC and 230 values 
for EBC were extracted and analysed by regression analysis. This analysis found base 
states values using SG valuations by members of the community to range from 0.668 
and 0.782 for EBC and 0.721 and 0.806 for MBC. Utility states were found to vary 
according to the time profile, with quality of life improving post diagnosis for EBC 
without recurrence and declining dramatically with disease progression for MBC. 
Important differences were found according to valuation method and valuer, with breast 
cancer patients valuing their own health giving the highest valuations. 
 
It is hoped that future research into quality of life in breast cancer will make greater use 
of multi-attribute health-related quality of life scales for which public preferences exist. 
Where utility values are generated there is a need to be much clearer about the time 
scale involved.  
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APPENDIX A 
 
Acronyms 
 
ABC: Advanced Breast Cancer 
BC: Breast Cancer 
BCS: Breast Conserving Surgery 
BCSRT: Breast Conserving Surgery with Radiation Therapy 
CMF: cyclophosphamide, methotrexate and 5-fluorouracil 
DCIS: Ductal Carcinoma In Situ 
EBC: Early Breast Cancer 
FAC: Fluorouracil, adriamycin and cyclophosphamide 
HALex: Health and Activity Limitation Index 
HDC: High Dose Chemotherapy 
HYE: Healthy Year Equivalents 
MBC: Metastatic Breast Cancer 
MRM: Modified radical mastectomy  
PCNV: Post Chemotherapy Nausea and Vomiting. 
PM: Prophylactic mastectomy  
PN: Peripheral neuropathy 
QoL: Quality of Life 
RCT: Randomised Controlled Trial 
SHE: Subjective Health Estimations 
SG: Standard Gamble 
SRE: Skeletal-Related Event 
SWD: States worse than dead 
TTO: Time Trade-Off 
VAS: Visual Analogue Scale 
WTP: Willingness to pay 
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Search strategy example: MEDLINE 
 
1. exp breast neoplasms/ 
2. exp neoplasms/ 
3. exp carcinoma/ 
4. exp adenocarcinoma/ 
5. exp breast/ 
6. or/2-4 
7. 5 and 6 
8. (carcinoma adj3 breast$).tw. 
9. (neoplas$ adj3 breast$).tw. 
10. (adenocarcinoma adj3 breast$).tw. 
11. (cancer$ adj3 breast$).tw. 
12. (tumour$ adj3 breast$).tw. 
13. (tumor$ adj3 breast$).tw. 
14. (malignan$ adj3 breast$).tw. 
15. or/8-14 
16. 1 or 7 or 15 
17. HALex.mp. [mp=ti, ot, ab, nm, hw, sh, ct] 
18. (euroqol or euro qol or eq5d or eq 5d).tw. 
19. qaly$.tw. 
20. quality adjusted life year$.tw. 
21. hye$.tw. 
22. health$ year$ equivalent$.tw. 
23. health utilit$.tw. 
24. hui.tw. 
25. quality of well being.tw. 
26. quality of wellbeing.tw. 
27. qwb.tw. 
28. (qald$ or qale$ or qtimes$).tw. 
29. (quality adjusted life day$ or quality adjusted life expectanc$ or quality adjusted 
survival$).tw. 
30. standard gamble$.tw. 
31. time trade off.tw. 
32. time tradeoff.tw. 
33. tto.tw. 
34. visual analog$ scale$.tw. 
35. discrete choice experiment$.tw. 
36. (sf6 or sf 6 or short form 6 or shortform 6 or sf six or sfsix or short form six).tw. 
37. (sf12 or sf 12 or short form 12 or shortform 12 or sf twelve or sftwelve or short form 
twelve).mp. [mp=ti, ot, ab, nm, hw, sh, ct] 
38. (sf6d or sf 6d or short form 6d or shortform 6d or sf 6 d).tw. 
39. health state$ utilit$.tw. 
40. health state$ value$.tw. 
41. health state$ preference$.tw. 
42. or/17-41 
43. letter.pt. 
44. editorial.pt. 
45. comment.pt. 
46. or/43-45 
47. 42 not 46 
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48. 16 and 47 
 
 27 
Table A.1: MBC utility values (117) & EBC utility values (230) 
 
VARIABLES Frequency (%) 
MBC 
Frequency (%) 
EBC 
Surgery (some values use more than one)   
 Mastectomy and reconstruction 0 12 (5.22%) 
 Mastectomy only 0 18 (7.83%) 
 BCS 0 52 (22.61%) 
 Non-specified surgery 0 32 (13.91%) 
 No surgery mentioned 0 128 (55.65%) 
   
Non-surgical treatment   
 Start of treatment 7 (5.98%) 0 
 Chemotherapy 57 (48.72%) 69 (30.00%) 
 Chemotherapy with N&V or toxicity 0 2 (0.87%) 
 Hormonal therapy 9 (7.69%) 10 (4.35%) 
 Radiotherapy 4 (3.42%) 35 (15.22%) 
 Treatment not specified or no 
treatment 
41 (35.04%) 114 (49.57%) 
   
Disease state   
 Response 17 (14.53%) 0 
 Stable 11 (9.40%) 0 
 Progression 12 (10.26%) 0 
 Terminal 9 (7.69%) 0 
 Disease state not specified 68 (58.12%) 0 
   
Side-effects   
 Peripheral neuropathy 9 (7.69%) 0 
 Oedema 9 (7.69%) 0 
 Febrile Neutropenia 3 (2.56%) 0 
 Sepsis 3 (2.56%) 0 
 Hypercalcaemia 3 (2.56%) 0 
 Side-effect 10 (8.55%) 0 
   
Who valued   
 Community 48 (41.03%) 51 (22.17%) 
 Clinician 42 (35.90%) 19 (8.26%) 
 Patients own health 13 (11.11%) 100 (43.48%) 
 Patients scenario 14(11.97%) 60 (26.09%) 
   
States worse than dead allowed 36 (30.77%) 79 (34.35%) 
   
Method of valuation   
 Standard Gamble 71 (60.68%) 67 (29.13%) 
 TTO top full health 8 (6.84%) 30 (13.04%) 
 TTO top not full health 5 (4.27%) 5 (2.17%) 
 VAS worst-best 6 (5.13%) 43 (18.70%) 
 VAS dead-full 19 (16.24%) 35 (15.22%) 
 EQ-5D UK 8 (6.84%) 38 (16.52%) 
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 Other 0 12 (5.22%) 
   
Risk of recurrence   
 Under 15% 0 4 (1.74%) 
 Over 15% 0 12 (5.22%) 
 No mention of risk of recurrence risk 0 214 (93.04%) 
   
Recurrence   
 Recurrence 0 37 (16.09%) 
 No recurrence 0 25 (10.87%) 
 Recurrence not mentioned 0 168 (73.04%) 
   
Time since diagnosis   
 Under 1 year 0 50 (21.74%) 
 1-5 years  0 30 (13.04%) 
 Time not mentioned 0 150 (65.22%) 
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APPENDIX B: 
 
Table B.1: Included studies in alphabetical order 
 
Study Health state description Health state value How valued Who valued Comments 
1. Bernhard 
et al. (2004) 
(56) 
Lymph node-negative BC – EBC states 
CMF (cyclophosphamide, methotrexate and 5-
fluorouracil) Toxicity (Median value at 3 
months – peak of toxicity) (n=276) 
 
Time without symptoms and toxicity (Median 
scores averaged within patients over the first 24 
months after randomisation, excluding the first 
3 months for patients with CMF) (n=384) 
 
Relapse (Median of the SHE scores averaged 
within patients over the first 6 months after 
relapse) (n=37) 
Median 
VAS: 0.76, TTO Power 
transformation 0.89 
 
 
VAS: 0.80, TTO Power 
transformation 0.91 
 
 
 
VAS: 0.62, TTO Power 
transformation 0.71  
VAS (Subjective Health 
Estimations SHE: 
anchored at worst to 
best health, patients 
asked to imagine 
spending the rest of 
their life in their current 
health state, then to 
value it.) 
 
Converted into TTO 
weights using a power 
transformation TTO=1-
(1-SHE)1.6 
Postmenopausal 
patients with 
lymph note-
negative BC, 
within a RCT for 
chemotherapy.  
 
Full sample, N = 
1669  
Age (median) 61.    
 
2. Bernhard 
et al. (2008) 
(57) 
IBCSG 
Trial, 
Europe, 
Australia 
and Asia 
(see also 
Table B.3) 
EBC and high risk of relapse 
Toxicity: 
Total sample (n=284) 
Time without symptoms and toxicity 
Total sample (n=292) 
Relapse 
Total sample (n=85) 
 
 
Mean 
VAS: 0.60, Transformed TTO 
0.77 
VAS: 0.78, Transformed TTO 
0.91 
VAS 0.60, Transformed TTO 
0.77 
 
VAS (SHE as above) 
 
Converted into TTO as 
above. 
344 EBC women 
at risk of relapse 
from IBCSG trial. 
Data table 
refers to 
means, but 
text refers to 
medians. 
3. Bonomi 
et al. (2008) 
(16) 
Screening states: 
Screening mammography 
 True negative 
Mean (SD), Median 
0.804 (0.14), 0.80 
0.891 (0.10), 0.90 
VAS anchored by death 
(0) and perfect health 
(1). 
English speaking 
women aged 50-
79 randomly 
Age given in 
categories, 
taking mid-
 39 
USA  False negative 
Diagnostic mammography 
 True positive 
 False positive 
Treatment 
 Lumpectomy 
 Mastectomy 
 Adjuvant radiation 
 Adjuvant chemotherapy 
 Antiestrogen therapy 
 Disease free at 1 year 
 Recurrence at 1 year 
 Palliation/end of life 
0.485 (0.21), 0.50 
0.553 (0.20), 0.50 
0.457 (0.21), 0.50 
0.810 (0.15), 0.80 
 
0.530 (0.21), 0.50 
0.483 (0.22), 0.50 
0.462 (0.23), 0.40 
0.397 (0.21), 0.50 
0.520 (0.22), 0.50 
0.768 (0.13), 0.50 
0.330 (0.19), 0.30 
0.358 (0.27), 0.30 
 
 
 
Each women valued 11 
of 14 possible clinical 
scenarios. 
 
N=131 
 
sampled from 
Group Health’s 
BC Screening 
Program. 137 
completed 
interviews: 
response rate 38%. 
Respondents more 
likely than non-
responders to have 
undergone biopsy 
or treatment for 
BC. 6 excluded 
due to lack of 
information on BC 
experience.  
point would 
give an 
average of 62. 
4. Cappelli 
et al. (2001) 
(22) 
BC states 
Lumpectomy and radiation therapy (n=59,60) 
Double mastectomy and chemotherapy (n=58, 
60) 
Breast cancer without treatment (n=44, 60) 
 
Positive BRCA states 
No prophylaxis, monitoring only. (n=60, 60) 
Preventive drug therapy (n=60, 60) 
Prophylactic bilateral mastectomy and 
oophorectomy (n=38,60) 
 
BC states 
Lumpectomy and radiation therapy (n=55,55) 
Double mastectomy and chemotherapy 
(n=55,55) 
BC without treatment (n=44,55) 
 
BC group 
SG 0.78 (.23), VAS 0.550 (.300) 
SG 0.68 (.27), VAS 0.289 (.258) 
 
SG 0.24 (.26), VAS 0.055 (.130) 
 
 
SG 0.84 (.19), VAS 0.433 (.288) 
SG 0.74 (.26), VAS 0.404 (.302) 
 
SG 0.61 (.30), VAS 0.211 (.230) 
 
HR group 
SG 0.73 (.28), VAS 0.440 (.263) 
SG 0.59 (.33), VAS 0.250 (.269) 
 
SG 0.17 (.22), VAS 0.063 (.099) 
 
SG  
VAS anchored at 0 
(least desirable) to 1 
(most desírable) 
 
13 hypothetical health 
states presented to 
participants including 
perfect health and death. 
 
Health status worse than 
dead assigned value of -
0.05. 
 
If dead not assigned 0 in 
VAS exercise SG 
values transformed such 
that 0 = dead. 
BC group (n=60) 
women diagnosed 
with BC before 
aged 50 within last 
2 years, being 
treated in Ottawa 
Regional Cancer 
Centre.  
High risk (HR) 
group (n=58) 
women without 
BC with at least 
one female blood 
relative diagnosed 
with BC before 
age 50. 
General 
population (GP) 
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Positive BRCA states 
No prophylaxis, monitoring only. (n=55,55) 
Preventive drug therapy (n=55,55) 
Prophylactic bilateral mastectomy and 
oophorectomy (n=42,55) 
 
BC states 
Lumpectomy and radiation therapy (n=49,49) 
Double mastectomy and chemotherapy 
(n=49,49) 
BC without treatment (n=30,49) 
 
Positive BRCA states 
No prophylaxis, monitoring only. (n=49,49) 
Preventive drug therapy (n=49,49) 
Prophylactic bilateral mastectomy and 
oophorectomy (n=27,49) 
 
SG 0.81 (.19), VAS 0.500 (.289) 
SG 0.65 (.33), VAS 0.299 (.237) 
 
SG 0.50 (.35), VAS 0.199 (.230) 
 
GP group 
SG 0.69 (.27), VAS 0.311 (.228) 
SG 0.55 (.33), VAS 0.198 (.219) 
 
SG 0.17 (.24), VAS 0.067 (.119) 
 
 
SG 0.75 (.25), VAS 0.447 (.240) 
SG 0.61 (.30), VAS 0.307 (.221) 
 
SG 0.44 (.31), VAS 0.126 (.129) 
group (n=51) 
women between 
18-50 never 
diagnosed with 
BC. 
5. Conner-
Spady et al. 
(2005) (58) 
Canada 
 
 
(some data 
also 
reported in 
Conner-
Spady et al. 
(2001) (83), 
which 
reports 
earlier study 
data from 
T1 to T3).  
EBC states: 
T1: Baseline prior to beginning treatment (n= 
48) 
 
T2: Day 1 of the third cycle of FAC (n=48) 
 
 
T3: 3 weeks after administration of HDC 
(n=48) 
 
T4: 6 months after enrolment or about 8 weeks 
post-HDC (n=45) 
 
T5: 12 months post enrolment (n=40) 
 
 
T6: 18 months post enrolment (n=36) 
Mean (SD) 
EQ-5D: 0.78 (0.18), QOL-VAS 
0.75 (0.04) 
 
EQ-5D: 0.75 (0.18), QOL-VAS 
0.77 (0.04) 
 
EQ-5D: 0.61 (0.29), QOL-VAS 
0.52 (0.06) 
 
EQ-5D 0.79 (0.19), QOL-VAS 
0.80 (0.04) 
 
EQ-5D 0.84 (0.19), QOL-VAS 
0.84 (0.04) 
 
EQ-5D 0.84 (0.13), QOL-VAS 
EQ-5D, UK tariff 
QOL-VAS. (How would 
you rate your quality of 
life over the past 2 
weeks: 0 very negative 
to 1 very positive.) 
 
EQ-5D distribution at 
T3 was negatively 
skewed and bimodal, 
major mode of 0.88 and 
minor mode of 0.29, but 
more symmetrical at T1, 
2 and 4. The bimodal 
distribution at T3 
appears to arise due to 
the higher number of 
52 patients from 
the Tom Baker 
Cancer Centre in 
Calgary, Alberta, 
1995-1998, with 
stage I and II BC 
at high risk of 
relapse (although 
under new system 
all patients would 
be stage III). 
 
Mean age 44.7 
(range 33-62). 
 
 
SD for VAS 
scores appear 
low, 
compared to 
Conner-Spady 
et al. (2001). 
 
26% of cases 
rated 1111 for 
EQ-5D at T1, 
but FLIC 
scores ranged 
from 110.41-
142.86 
suggesting 
ceiling effect 
with EQ-5D 
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T7: 24 months post enrolment (n-37) 
 
0.88 (0.03) 
 
EQ-5D 0.89 (0.13), QOL-VAS 
0.89 (0.03) 
level 3’s in ‘usual 
activity’ at T3, and the 
subsequent inclusion of 
the N3 term. 
 
6. Cykert et 
al. (2004) 
(27) 
USA 
EBC, MBC & side effect states: 
Curable BC 
Curable endometrial cancer 
Metastatic cancer then death within 2 years 
Stroke: mild debility 
Stroke: moderate debility 
Stroke: severe debility 
DVT: No postphlebitic syndrome 
DVT: Postphlebitic syndrome 
Pulmonary embolism 
 
Hot flushes - 85% of respondents reported no 
QoL decrement so this outcome is not included.  
Mean 
0.83 
0.83 
0.3 
0.7 
0.7 
0.2 
0.86 
0.90 
0.81 
SG. Anchored at death-
BC cure and avoiding 
treatment. 
 
Study notes that values 
were converted to utility 
scores where 0 =dead 
and 1 = excellent health, 
although details of this 
are not given. 
106 women aged 
50+ from urban 
areas of North 
Carolina and south 
Florida, 35% were 
African-American. 
Mean age 60.  
 
7. De Haes 
et al. (1991) 
(17) 
Netherlands 
EBC, MBC & Screening states: 
3 months – 1 year after mastectomy (one table 
says 2 months?) (10 months) 
 
Palliative + surgery (lasting 5 weeks) 
 
Palliative + chemotherapy (4 months) 
 
Initial surgery (2 months) 
 
Palliative + hormonal therapy (14 months) 
 
Initial radiotherapy (2 months) 
 
Initial hormonal therapy (2 years) 
 
 
Mean 0.65 (SD .165) Med. 0.64 
Transformed  = 0.884 
 
Mean .46 (SD .164) Med .41 
Transformed = 0.617 
Mean .36 (SD .170) Med .34 
Transformed = 0.531 
Mean .62 (SD .155) Med .67 
Transformed = 0.867 
Mean .47 (SD .191) Med .45 
Transformed = 0.663 
Mean .60 (SD .152) Med .59 
Transformed = 0.803 
Mean .63 (SD .168) Med .61 
Transformed = 0.820 
VAS. Anchored at 
worst imaginable to 
best.  
 
Transformed into a 
utility score, using a 
power function of 
TTO=1-(1-VAS) ^1.82 
N=27  
 
n=15 employees 
from the 
department of 
public health and 
social medicine, 
Netherlands. 
 
n=12 experts in 
BC treatment and 
epidemiology in 
the Netherlands. 
 
Age of 
respondents not 
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Initial chemotherapy (6 months) 
 
3 months – 1 year after breast conserving 
surgery (one table says 2 months?) (10 months) 
Palliative + radiotherapy (1 month) 
 
Terminal illness (1 month) 
 
Screening attendance (1 week) 
 
Diagnostic phrase (5 weeks) 
 
Disease-free > 1 year after mastectomy  
 
Disease-free > 1 year after breast-conserving 
therapy 
 
Mean .50 (SD .176) Med .50 
Transformed 0.717 
Mean 0.71 (SD 0.155) Med .74  
Transformed 0.914 
 
Mean .43 (SD .164) Med .38 
Transformed 0.591 
Mean .19 (SD .153) Med .17 
Transformed 0.288 
Mean .92 (SD .069) Med .94 
Transformed 0.994 
Mean .71 (SD .142) Med .71 
Transformed 0.895 
Mean .77 (SD .127) Med .80 
Transformed 0.947 
Mean .82 (SD .115) Med .83 
Transformed 0.960  
stated. 
8. De 
Koning et 
al. (1991) 
(18) 
Netherlands 
MBC, EBC and screening states 
Adjuvant hormonal treatment (2 or 5 years) 
Advanced disease treatment (20 months) 
Biopsy due to false positive (5 weeks) 
Biopsy with benign result (5 weeks) 
Breast conserving therapy (10 months) 
Terminal, advanced (1 month) 
Mammographic screening (1 week) 
Primary radiation (2 months) 
Primary surgery (2 months) 
Median 
0.82 
0.63 
0.89 
0.89 
0.93 
0.29 
0.99 
0.80 
0.87 
VAS. Anchored at 
worst possible to perfect 
health. 
N=27 clinicians or 
public health 
experts 
 
9. Gerard et 
al. (1999) 
(19) 
UK 
 
Some data 
Screening states: 
Short term 
True negative 
False positive 
 
Long term 
Mean (SD) 
 
0.94 (0.14) 
0.79 (0.21) 
 
 
Respondents classified 
screening states into 
EQ-5D dimensions. 
 
EQ-5D assuming 
dimensions 1 and 2 are 
N=440 
Community. 
Women. 
209 of whom aged 
40-44 and 231 
aged 45-64. 
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is also 
reported in 
Johnston et 
al. (1998) 
(20) 
True positive 
False negative 
0.48 (0.30) 
0.45 (0.30) 
constant. UK tariff. 
Also conducted TTO. 
12 months and rest of 
life. Anchored at dead-
full health.  
 
SWD not permitted 
10. Gordon 
et al. (2005) 
(59) 
Australia 
EBC states 
DAART (n=36) 
STRETCH (n=31) 
Control (n=208) 
 
Regression analysis to control for age, tumour 
size, presence of co-morbidities, income, health 
insurance, living alone, perceived stress at 
baseline. 
 
DAART  
STRETCH  
Control  
 
Mean (SD) 
0.77 (SD 0.19) 
0.79 (SD 0.18) 
0.73 (SD 0.17) 
 
 
 
 
 
 
0.84 (95% CI 0.74-0.90) 
0.80 (95% CI 0.73-0.87) 
0.72 (95% CI 0.70-0.75) 
VAS (SHE)   
Anchored at worst 
possible to best 
possible. 
Diagnosed 
primary BC, 
unilateral disease, 
aged 25-74. 
Allocated into:  
n=36 DAART 
(Domiciliary 
Allied Health and 
Acute Care 
Rehabilitation 
Team). Mean age 
59.   
n=31 STRECH 
(Strength through 
recreation exercise 
togetherness care 
health). Mean age 
54  
n=208 Control 
group sourced 
from another 
sample. Mean age 
55. 
Women were 
excluded 
from the 
DAART and 
STRETCH 
groups if they 
were “too ill”. 
11. Grann et 
al. (1998) 
(38) 
EBC & MBC states 
BC 
Metastatic  
Mean (IQR) 
0.89 (IQR 0.87-1.00) 
0.63 (IQR 0.50 – 0.83) 
TTO. Anchored at death 
to health state prior to 
disability. 
54 community-
based. 
Mean age 38 
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USA 
12. Grann et 
al. (1999) 
(23) 
EBC, MBC and preventative states: 
BC patients without known metatstatic disease.  
G4, n=20 
Reference group (age range 33-50) 
 
Breast cancer. Therapy includes mastectomy 
with reconstruction and chemotherapy. 
Afterwards you feel well and resume your 
previous activities and social and personal life. 
Told you have 30% risk of recurrence. Women 
like you live on average to 70. 
 
 
 
Metastatic disease (breast or ovarian). It has 
partially incapacitated you. You must spend 
50% of your time at home although you are 
able to handle your own personal care and local 
shopping. You have pills that control your pain 
fairly effectively, but they cause moderate 
nausea and fatigue. Your life expectancy is 3 
years beyond your current age.  
 
Prophylactic mastectomy (double). BRCA1 or 
BRCA2 positive. Reduce risk of BC by 90%. 
 
 
 
 
 
 
 
Chemoprevention. BRCA1 or BRCA2 
Mean (SD) 
VAS: .83 (.12) 
 
VAS: .84 (.15) 
 
VAS:G1 .58 (.19), TTO:G1 0.87 
(.20) 
VAS:G2 .57 (.23), TTO:G2 0.68 
(.35) 
VAS:G3 .66 (.17), TTO:G3 0.83 
(.22) 
VAS:G4 .64 (.21), TTO:G4 0.89 
(.13) 
 
VAS:G1 .27 (.18), TTO:G1 0.73 
(.27) 
VAS:G2 .34 (.29), TTO:G2 0.52 
(.35) 
VAS:G3 .34 (.22), TTO:G3 0.59 
(.27) 
VAS:G4 .40 (.26), TTO:G4 0.76 
(.31) 
 
VAS:G1 .56 (.22), TTO:G1 0.86 
(.21) 
VAS:G2 .63 (.23), TTO:G2 0.82 
(.39) 
VAS:G3 .60 (.26), TTO:G3 0.76 
(.26) 
VAS:G4 .66 (.31), TTO:G4 0.85 
(.15) 
 
TTO:G1 0.90 (0.15) 
VAS. Anchored at death 
to best possible. 
 
TTO. Anchored at death 
to disease free state 
(“eliminate the 
condition described in 
the vignette”). Living 
till 70. 
G1: Young 
women 
community n=93. 
Mean age 26 
 
G2: Older women 
community n=42. 
Mean age 40 
 
G3: High risk 
women 
community n=22. 
Mean age 43 
 
G4: Breast Cancer 
n= 20. Mean age 
43 (range 33-50) 
Test-retest on 
18 response 
young group. 
7 pairs 
correlation 
higher than 
0.7, 
remaining 11 
higher than 
0.5. VAS 
rating for 
mastectomy 
(0.515) 
lowest. 
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negative. 1 pill every day for 5 years. Reduce 
risk by 50% 
 
 
TTO:G2 0.79 (0.29) 
TTO:G3 0.81 (0.25) 
TTO:G4 0.85 (0.22) 
13. Hauser 
et al. (2001) 
(39) 
USA 
 
Abstract  
 
MBC states: 
Partial response (PR) 
PR with severe peripheral edema 
PR with severe PN 
Before second line treatment begins 
Stable disease 
Late progressive disease 
Terminal disease 
Sepsis 
Mean (SD) 
0.84 (.11) P, 0.71(.22) N  
0.78 (.17) P, 0.63(.24) N 
0.76 (.13) P, 0.56 (.24) N 
0.73 (.16) P, 0.59 (.22) N 
0.72 (.15) P, 0.54 (.22) N 
0.63 (.18) P, 0.45 (.25) N 
0.40 (.26) P, 0.19 (.21) N 
0.39 (.25) P, 0.20 (.23) N 
SG 45 patients (P) 
57 oncology 
nurses (N) 
Patients have 
higher 
utilities than 
nurses. 
All 
differences 
are 
significant. 
14. Hayman 
et al. (1997) 
(60) 
USA 
EBC states: 
WITH PATIENTS 
A. Conservative surgery and radiation therapy 
without local recurrence to date but with a 10% 
risk of local recurrence that could be salvaged 
with mastectomy and reconstructive surgery. 
(SG n=97) 
 
B. Conservative surgery and radiation therapy 
with a local recurrence salvaged with 
mastectomy and reconstructive surgery (SG 
n=90) 
 
C. Conservative surgery alone without a local 
recurrence to date but with 40% risk of local 
recurrence that would be salvaged with either 
breast-conserving surgery and radiation therapy 
or mastectomy and reconstructive surgery. (SG 
n= 96) 
 
 
PATIENTS 
Mean 0.92 (sd 0.15) Med. 0.97 
IQR 0.91-0.99 Range 0.05-1.00 
 
 
 
 
Mean 0.82 (sd 0.19) Med. 0.85 
IQR 0.76-0.95 Range 0-0.99 
 
 
 
Mean 0.88 (sd 0.18) Med 0.92. 
IQR 0.86-0.98 Range 0-1.0 
 
 
 
 
 
VAS. Anchored at least 
desirable to most 
desirable. Not reported 
but used to identify the 
lowest rank health state 
for the cascading SG 
method. 
 
SG. Partial cascading. 
Highest four health 
sates ranked using best 
outcome and lowest 
ranked health.  
Anchored death-perfect 
health. 
 
SWD not discussed. 
Patients. N=97. 
Median age 56 
(range 30-84)  
Patients with stage 
I or II tumours (88 
had stage I), who 
had undergone 
breast-conserving 
surgery followed 
by radiotherapy 
(35 also had 
chemotherapy). 
They had to have 
completed all 
therapy (except 
tamoxifen) at least 
6 months, not 
more than 24 
months prior to the 
interview 
Preference for 
stage A over 
C suggests the 
increased risk 
of recurrence 
(10% to 40%) 
outweighs the 
side effects of 
radiotherapy. 
 
A range of 
additional 
data were 
collected for 
patients, 
however, 
none of the 
factors 
explained 
more than 5% 
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D. Conservative surgery alone with a local 
recurrence salvaged with conservative and 
radiation therapy (SG n=94) 
 
E. Conservative surgery alone with a local 
recurrence salvaged with mastectomy and 
reconstructive surgery. (SG n = 92) 
 
WITH NURSES 
A. (SG n=20) 
 
 
B.  (SG n=20) 
 
 
C. (SG n= 20) 
 
 
D. (SG n=20) 
 
 
E. (SG n=20)   
Mean 0.87 (sd 0.18) Med. 0.94 
IQR 0.84-0.97. Range 0-1.0 
 
 
Mean 0.81 (sd 0.20) Med 0.88 
IQR 0.75-0.95 Range 0-0.99 
 
 
NURSES 
Mean 0.92 (sd 0.08) Med. 0.94 
IQR 0.88-0.97. Range 0.7-1.0 
 
Mean 0.78 (sd 0.18) Med. 0.81 
IQR 0.75-0.87. Range 0.15 -0.99 
 
Mean 0.88 (0.09) Med 0.89 IQR 
0.84-0.96 Range 0.66-0.99 
 
Mean 0.84 (0.14) Med 0.86 IQR 
0.76-0.95. Range 0.41-0.99 
 
Mean 0.78 (0.20) Med 0.85 IQR 
0.71-0.90 Range 0.15-0.96 
 
(although 11 did 
not meet this 
criteria). No 
history of 
recurrent or 
contralateral breast 
cancer. 
 
Female oncology 
nurses. N= 20. 
Median age 37. 
of the 
variability in 
health state 
utilities, nor 
differences 
between 
states.  
 
Health states 
are described 
in detail (see 
paper).  
15. Hayman 
et al. (2005) 
(61) 
EBC states: 
A: BCS and RT without recurrence. Risk of 8% 
non-invasive and 4% invasive recurrence. 
 
 
B: Non-invasive recurrence salvaged with 
mastectomy after initial treatment with BCS 
and RT. 
 
C: An invasive recurrence salvaged with 
Mean (SD) 
Mean: PUB 0.90 (.14) DCIS 
0.93 (.13) 
Median: PUB 0.95 DCIS 0.97 
 
Mean: PUB 0.88 (.16) DCIS 
0.89 (.16) 
Median: PUB 0.94 DCIS 0.95  
 
Mean: PUB 0.81 (.19)  DCIS 
SG. Partial cascading. 
Initially ranked using 
anchors of the best and 
worst of 8 health states 
from the ranking. 
Lowest rank assessed 
against death and 
optimal health 
 
SWD not discussed.   
210 healthy 
women in a 
university-based 
wellness clinic. 
Mean age 50 
(range 19-84) 
 
120 patients with 
DCIS treated with 
lumpectomy and 
Medians 
higher than 
means for 
both groups:  
skewed 
upwards 
 
Patients 
preferred 
having 
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mastectomy after initial treatment with BCS 
and RT. 
 
D: BCS alone without recurrence. Risk of 13% 
non-invasive and 13% invasive recurrence. 
 
 
E: A non-invasive recurrence salvaged with 
BCS and RT after initial treatment with BCS 
alone. 
 
F: A non-invasive recurrence salvaged with 
mastectomy after initial treatment with BCS 
alone. 
 
G: An invasive recurrence salvaged with BCS 
and RT after initial treatment with BCS alone 
 
 
H: An invasive recurrence salvaged with 
mastectomy after initial treatment with BCS 
alone. 
 
 
0.80 (.27) 
Median: PUB 0.85  DCIS 0.91  
 
Mean: PUB 0.90 (.15)  DCIS 
0.91 (.15)  
Median: PUB 0.95  DCIS 0.96  
 
Mean: PUB 0.90 (.15)  DCIS 
0.89 (.19) 
Median: PUB 0.95  DCIS 0.95 
 
Mean: PUB 0.89 (.15) DCIS 
0.87 (.21)  
Median: PUB 0.94  DCIS 0.95   
 
Mean: PUB 0.81 (.19) DCIS 
0.79 (.26)  
Median: PUB 0.87  DCIS 0.91  
 
Mean: PUB 0.84 (.18) DCIS 
0.75 (.29)  
Median: PUB 0.91  DCIS 0.86 
 
 
 
 
 
 
RT. Mean age 61 
(range 42-82). 
Mean of 39 
months since 
completion of RT.  
 
received RT 
after 
recurrence 
(C>H), 
whereas non 
patients 
preferred not 
to have 
received RT 
(H>C). 
 
Few 
statistically 
significant 
differences 
between 
patients and 
non-patients.  
 
Differences in 
valuations 
were not 
explained by 
socio-
demographic 
or clinical 
factors.  
16. Hurny 
et al. (1998) 
(40) 
Switzerland 
MBC or inflammatory BC states: 
VAS (dead-perfect health) 
 
VAS (worst health – perfect health) 
 
VAS (worst health-perfect health) 
 
Mean 0.659 (SD .203) Med .65 
(range 0.18-1) 
Mean 0.613 (SD.239) Med .62 
(range .03-.99) 
 
VAS. Anchored at 
dead- perfect health 
 
VAS. Anchored at 
worst possible health - 
perfect health 
84 ambulatory 
patients with 
metastatic or 
inflammatory BC 
seen for treatment 
or routine check-
Two VAS 
scores had 
correlation of 
0.8. Lack of 
agreement 
was worst for 
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Receiving hormonal therapy (n=36) 
Receiving mild chemotherapy (n=15) 
Receiving intensive chemotherapy (n=33) 
Mean .628 (SD .234) 
Mean .651 (SD .221) 
Mean .483 (SD .285) 
 
 
TTO. Anchored at 
excellent health for 1 
year. (but given the 
severity of illness this is 
approximate life 
expectancy). 
Asked as (12, 11, 9, 6, 
3, 1 or 0 months) 
TTO means not 
reported. 
 
ups hospitals in 
Switzerland. 
Eligible patients 
aged 20-75, had 
experience of 
chemotherapy, had 
ECOG 
performance state 
of 0-3. 
 
 
those at the 
higher end.  
Respondent 
age reported 
as 
frequencies. 
19 at <= 45, 
27 at 46-55, 
24 at 56-65, 
14 at >=65. 
(Estimated at 
54) 
17. Hutton 
et al. (1996) 
(41) 
 
See also 
Brown et al. 
(2001) (50) 
& Brown 
and Hutton 
(1998) (51) 
& Kearney 
et al. (1999) 
(52) 
MBC states: 
Partial response 
Partial response and severe peripheral oedema 
Stable disease 
Before second line therapy beings 
Partial response and severe PN 
Progressive disease 
Sepsis 
Terminal disease 
Mean (Av. 5 countries) 
Av: 0.81 UK: 0.84  
Av: 0.75 UK: 0.78 
Av: 0.62 UK: 0.62 
Av: 0.59 UK: 0.56 
Av: 0.53 UK: 0.62 
Av: 0.41 UK: 0.33 
Av: 0.20 UK: 0.16 
Av: 0.16 UK: 0.13 
 
 
VAS. Anchored at 
worst possible – best 
possible. Used for 
cascading. 
 
SG. Anchored at worst 
possible – best possible. 
 
 
 
129 oncology 
nurses from 5 
countries. 
 
Total sample, 
mean age 33.7, 
n=129 
Values 
included are 
those from the 
combined 5 
country 
sample.  
18. Isogai et 
al. (2008) 
(36) 
 
Abstract 
only 
BC general: 
N=151 
Mean 
0.80 (0.16) 
EQ-5D 151 consecutive 
BC patients 
irrespective or 
stage or treatment 
attending at an 
outpatient clinic. 
Time since 
diagnosis 0.1 to 25 
 
 49 
years. Mean age 
55.2 (12.5) 
19. Jansen 
et al. (1998) 
(26) 
Netherlands 
EBC states: 
Temporary states 
TTO: Actual health state (n=61) 
SG: Actual health state (n=61) 
TTO: Radiotherapy scenario  (n=61) 
SG: Radiotherapy scenario (n=61) 
TTO: Chemotherapy scenario (n=35) 
SG: Chemotherapy scenario (n=35) 
 
Actual health 
Early state BC following mastectomy or 
lumpectomy, before radiotherapy 
 
Radiotherapy state: 
Daily radiotherapy over 6 weeks, then 4 and 
half months of side effects. 
Physical: skin reactions, fatigue, listlessness 
Psychological: Anxiety and worry about future 
Social Limitations: to daily and social activities 
 
Chemotherapy state: 
During 6 months 1 or 2 hospital visits per 3 
weeks for chemotherapy via infusion.  
Physical: nausea, fatigue, hair loss 
Psychological: Dissatisfaction with own body 
Social Limitations: to daily and social activities 
Mean (SD) 
 
0.94 (0.12) 
0.94 (0.11) 
0.89 (0.13) 
0.87 (0.19) 
0.74 (0.26) 
0.75 (0.27) 
Chained TTO and SG, 
using an anchor state of 
hospitalisation 
following an accident. 
 
Transformed to a scale 
from dead to good 
health. 
 
In the TTO one third 
(34%) of patients 
preferred the anchor 
state to chemotherapy 
(34%). 
 
In SG 6% preferred the 
anchor state to 
chemotherapy. 
 
Utilities were not 
computed for these 
patients. 
 
SWD were not allowed. 
EBC patients n= 
61. After 
mastectomy or 
lumpectomy, 
before 
radiotherapy 
treatment. 
 
24 patients rating 
the anchor state 
above 
chemotherapy 
therefore this state 
could not be 
estimated for these 
patients.  
Median age 57 
(range 33-82).  
Authors note 
that using the 
6 month 
period avoids 
the downward 
bias caused 
by 
discounting in 
TTO.  
 
  
20. Jansen 
et al. (2000) 
(25) 
Netherlands 
EBC states: 
Actual  
T1: VAS (n=55) 
T1: TTO (n=54). (Value also appears in Jansen 
et al. (1998)) 
Mean (SD) 
 
0.81 (0.12) 
0.94 (0.12) 
 
VAS. Anchored at dead 
to perfect health. 
Chained TTO 
Chained SG. 
 
Patients referred to 
Leiden University 
Medical Centre for 
5-7 week course of 
radiotherapy after 
Valuation for 
the anchor 
state changes 
little. 
Own health 
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T1: SG (n=51) (Value also appears in Jansen et 
al. (1998)) 
 
T2: VAS (n=55) 
T2: TTO (n=54) 
T2: SG (n=51) 
 
T3: VAS (n=55) 
T3: TTO (n=54) 
T3: SG (n=51) 
 
Radiotherapy scenario 
T1: VAS (n=55) 
T1: TTO (n=54) 
T1: SG (n=51) 
 
T2: VAS (n=55) 
T2: TTO (n=54) 
T2: SG (n=51) 
 
T3: VAS (n=55) 
T3: TTO (n=54) 
T3: SG (n=51) 
 
Chemotherapy scenario 
T1: VAS (n=53) 
T1: TTO (n=25) 
T1: SG (n=36) 
 
T2: VAS (n=53) 
T2: TTO (n=25) 
T2: SG (n=36) 
 
T3: VAS (n=53) 
T3: TTO (n=25) 
0.94 (0.11) 
 
 
0.79 (0.14) 
0.92 (0.13) 
0.91 (0.19) 
 
0.81 (0.13) 
0.97 (0.08) 
0.91 (0.20) 
 
 
0.75 (0.13) 
0.89 (0.13) 
0.88 (0.19) 
 
0.73 (0.16) 
0.91 (0.13) 
0.86 (0.18) 
 
0.73 (0.13) 
0.90 (0.17) 
0.88 (0.24) 
 
 
0.53 (0.18) 
0.75 (0.24) 
0.68 (0.28) 
 
0.49 (0.16) 
0.75 (0.25) 
0.75 (0.25) 
 
0.51 (0.16) 
0.76 (0.26) 
Method similar to 
Jansen et al. (2001) 
 
T1: shortly before 
radiotherapy 
T2: final week of 
radiotherapy 
T3: two months after 
radiotherapy 
lumpectomy or 
mastectomy, 
excluding those 
with prior 
experience of 
radiotherapy.  
 
 (n=55). Median 
age 57 (33-82) 
89% had 
lumpectomy. 
 
Chemotherapy 
scenario was only 
valued by those 
who did not prefer 
the anchor state to 
the chemotherapy 
state.  
 
state valued 
higher than 
radiotherapy 
scenario at T3 
(sig for VAS 
and SG but 
not TTO) 
Valuations of 
radiotherapy 
remained 
fairly stable. 
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T3: SG (n=36) 0.71 (0.28) 
21. Jansen 
et al. (2001) 
(62) 
 
Netherlands 
EBC states: 
Chemotherapy Group 
T1: VAS (n=42) 
T1: TTO (n=43) 
T1: SG (n=37) 
 
T2: VAS (n=42) 
T2: TTO (n=43) 
T2: SG (n=37) 
 
T3: VAS (n=42) 
T3: TTO (n=43) 
T3: SG (n=37) 
 
Control group 
T1: VAS (n=51) 
T1: TTO (n=45) 
T1: SG (n=45) 
 
T2: VAS (n=51) 
T2: TTO (n=45) 
T2: SG (n=45) 
 
T3: VAS (n=51) 
T3: TTO (n=45) 
T3: SG (n=45) 
 
For the chemotherapy group utility according to 
VAS lower in T3 than T2 or T1. 
 
Wider range of values for the control group. 
Lower values than from chemotherapy group. 
However, utilities for the anchor state were 
Median (IQR) 
 
0.69 (0.55-0.80) 
0.88 (0.75-0.96) 
0.92 (0.80-1.00) 
 
0.69 (0.52-0.83) 
0.87 (0.79-0.92) 
0.96 (0.79-1.00) 
 
0.62 (0.50-0.75) 
0.87 (0.72-0.96) 
0.93 (0.80-0.99) 
 
 
0.50 (0.37-0.71) 
0.50 (-0.11-0.84) 
0.58 (-0.90-0.90) 
 
0.49 (0.35-0.64) 
0.77 (-0.02-0.88) 
0.73 (-0.03-0.91) 
 
0.50 (0.37-0.65) 
0.69 (-0.02-0.88) 
0.82 (0.49-0.93) 
 
 
 
 
 
 
 
VAS. Anchored at dead 
to perfect health. 
Chained TTO 
Chained SG 
 
Chaining TT0 involved 
6 months chemotherapy 
versus shorter period in 
the anchor health state, 
followed by rest of life 
in good health.  
Anchor state was 
hospitalization caused 
by serious accident. 
Anchor state is valued 
as 6 months versus 
shorter time in full 
health both followed by 
death.  
 
Chaining SG involved 6 
months chemotherapy 
versus chance of full 
health or anchor state 
for 6 months, followed 
by good health for 
remainder of life.  
 
Allowed both states to 
be worse than dead. 
 
T1: Before 
chemotherapy 
Patients with early 
BC recruited from 
5 hospitals in the 
Netherlands. 
Those scheduled 
for adjuvant 
chemotherapy 
included if they 
had not undergone 
chemotherapy 
previously (n=43). 
Mean age 42 
 
Control group: 
women with early 
stage BC not 
advised to have 
systemic adjuvant 
therapy of for 
whom hormonal 
therapy 
(tamoxifen) was 
prescribed (n=51). 
Mean age 56 
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slightly higher in the chemotherapy group at T2 
by SG and T3 by SG and TTO (non-sig.). 
Might be due to age, but within each group age 
was not related to utilities.  
‘Most likely’ patients may have adapted to the 
decision for chemotherapy – the ‘anticipated 
adaptation’ – patients wish to believe they have 
made the correct decision. The control group 
“may be more negatively inclined toward a 
treatment that was not offered (or was turned 
down”. Adaptation to the decision for treatment 
rather than the treatment itself.  
 
Chemotherapy group. Own health state during 
chemotherapy 
VAS (n=42) 
TTO (n=42) 
SG (n=37) 
 
In all methods significantly higher than their T2 
valuation. This effect is termed 
‘nocorresponding description’, may result from 
differences between the description and the 
actual health state, or cognitive bias, or may 
have involved a more emotionally laden ‘hot’ 
judgement and aroused more emotional 
conflict. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Median (IQR) 
0.79 (0.71-0.89) 
0.93 (0.88-1.00) 
0.97 (0.85-1.00) 
T2: midway through 
chemotherapy 
T3: 1 month after 
chemotherapy 
 
Chemotherapy 
description designed 
based on the experience 
of 6 oncologists and 5 
BC patients with early 
BC who had undergone 
chemotherapy.  
 
Chemotherapy state: 
One or 2 hospital visits 
every 3 weeks for 6 
months for 
chemotherapy via 
infusion.  
Physical: nausea, 
fatigue, hair loss, 
difficulty in carrying 
out strenuous activities, 
frequent need to rest 
Psychological: 
dissatisfaction with 
one’s body. 
Social: Limitations to 
work or other daily 
activities, restrictions on 
social activities. 
22. Jansen 
et al. (2004) 
(63) 
EBC states: 
After adjuvant chemo. Choice (n= 54) 
After adjuvant chemo. No Choice (n = 105) 
Mean  
VAS: 0.77, EQ-5D: 0.84  
VAS: 0.75, EQ-5D: 0.82 
VAS. Anchored at death 
and perfect health 
 
448 patients with 
EBC. 
 
Values found 
to reduce with 
age. But no 
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Netherlands No adjuvant chemo. Choice (n=28) 
No adjuvant chemo. No choice (n= 174) 
 
 
VAS: 0.69, EQ-5D: 0.74 
VAS: 0.77, EQ-5D: 0.83 
 
 
 
EQ-5D, UK tariff Perceived choice 
n= 89. Mean age 
57 
 
Perceived no-
choice n = 316. 
Mean age 59 
 
Excluded: Those 
with metastatic 
disease 
sig. 
differences 
with 
perceived 
choice. No 
chemo choice 
group scores 
lowest, 
authors 
suggest may 
be due to fear 
of recurrence 
and having 
made the 
incorrect 
decision. 
23. 
Johnston et 
al. (1998) 
(20) 
 
UK 
Screening states: 
 
TTO  
True negative 
 
False positive 
 
True positive 
 
False negative 
 
 
VAS (Rescaled 0 death 1 best imaginable) 
True negative 
 
 
False positive 
 
 
 
TTO 
Mean 0.91 (sd .21) Med. 0.98 
(IQR 0.96-0.99) 
Mean 0.66 (sd .38) Med. 0.83 
(IQR 0.22-0.96) 
Mean 0.66 (sd 0.29) Med. 0.75 
(IQR 0.55-0.95) 
Mean 0.66 (sd 0.29) Med 0.75 
(IQR 0.45-0.95) 
 
VAS 
Mean 0.92 (sd 0.18) Med. 1.0 
(IQR 0.9-1.0) 
 
Mean 0.67 (sd 0.28) Med. 0.75 
(IQR 0.50-0.90) 
VAS. Anchored best 
imaginable health. 
Rescaled to death-good 
health. 
 
TTO. 
Valued for 12 months. 
 
SWD not allowed. 
N=440 
Women aged 40-
44 n=209 
Women aged 50-
64 n= 231 
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True positive 
 
 
False negative 
 
 
Mean 0.75 (sd 0.25 Med. 0.80 
(IQR 0.60-0.98) 
 
Mean 0.60 (sd 0.27) Med. 0.63 
(IQR 0.40-0.80) 
24. 
Kimman et 
al (2009) 
(64) 
EBC 
2 weeks post treatment (T0) 
 A. Large deterioration (n=23) 
 B. Small deterioration (n=14) 
 C. No change (n=55) 
 D. Small improvement (n=28) 
 E. Large improvement (n=72) 
 
12 months post treatment (T1) 
 A. Large deterioration (n=23) 
 B. Small deterioration (n=14) 
 C. No change (n=55) 
 D. Small improvement (n=28) 
 E. Large improvement (n=72) 
 
Group determined by EORTC QLQ-C30 scores 
Mean 
 
EQ-5D: 0.72, EQ-VAS: 0.730 
EQ-5D: 0.73, EQ-VAS: 0.744 
EQ-5D: 0.82, EQ-VAS: 0.790 
EQ-5D: 0.78, EQ-VAS: 0.709 
EQ-5D: 0.71, EQ-VAS: 0.650 
 
 
EQ-5D: 0.57, EQ-VAS: 0.598 
EQ-5D: 0.72, EQ-VAS: 0.694 
EQ-5D: 0.82, EQ-VAS: 0.799 
EQ-5D: 0.80, EQ-VAS: 0.777 
EQ-5D: 0.83, EQ-VAS: 0.774 
EQ-5D (UK tariff), EQ-
VAS 
 
Of 220 eligible patients 
29 failed to complete 
the study (10 dropped 
out and 19 did not 
complete instruments). 
192 female 
patients treated for 
BC with curative 
intent, no 
concomitant 
tumours or co-
morbidity 
requiring hospital 
visits. Treatment 
included surgery 
and/or 
radiotherapy 
and/or 
chemotherapy. 
Age for full 
sample 55.8 (10.1) 
 
25. Ko et al. 
(2003) (33) 
USA 
General BC states: 
 
Acute < 1 year after diagnosis of BC (n = 64) 
Short term 1 to 5 (n =73) 
Long term >5 (n =217) 
 
Mean (SD) 
 
0.62 (0.27)  
0.69 (0.24) 
0.71 (0.24)  
 
HALex scoring 
algorithm based on a 
multi-attribute utility 
scaling from responses 
to activities of daily 
living and perceived 
health status. (see paper 
for details) 
 
Converted to 0 near 
death state to 1 perfect 
National Health 
Interview Survey 
(NHIS), US 
337 BC. Mean age 
at diagnosis of BC 
was 56. 
 
 
 55 
health with no 
limitations. 
26. Launois 
et al. (1996) 
(42) 
France 
 
SD given 
by the 
author. 
MBC states: Second line-chemotherapy  
 
Before starting chemotherapy 
Minor toxicities 
Severe skin reactions 
Severe arthralgia / myalgia  
Febrile neutropenia without hospitalisation 
Early progression 
Gastrointestinal toxicity with hospitalisation 
Febrile neutropenia with hospitalisation 
Confirmed responder 
Confirmed responder with oedema 
Confirmed responder treatment interrupted for 
severe oedema 
Confirmed responder treatment interrupted for 
severe neuropathy 
Confirmed responder with severe neuropathy  
Stable  
Stable with severe oedema 
Stable treatment interrupted for severe oedema 
Stable treatment interrupted for severe 
neuropathy 
Stable with severe neuropathy 
Progression 
Progression treatment interrupted for severe 
oedema 
Progression with severe oedema 
Progression with severe neuropathy 
Progression treatment interrupted for severe 
neuropathy 
Terminal care 
Mean (SD) 
 
0.86 (0.13) 
0.76 (0.15) 
0.72 (0.24) 
0.72 (0.08) 
0.66 (0.16) 
0.52 (0.27) 
0.48 (0.16) 
0.47 (0.26) 
0.81 (0.19) 
0.74 (0.15) 
0.64 (0.11) 
 
0.64 (0.18) 
 
0.57 (0.23) 
0.75 (0.19) 
0.73 (0.12) 
0.58 (0.26) 
0.58 (0.25) 
 
0.50 (0.21) 
0.65 (0.17) 
0.58 (0.13) 
 
0.53 (0.21) 
0.50 (0.19) 
0.45 (0.12) 
 
0.25 (0.21) 
SG. 
 
No discussion of 
method or anchors used. 
20 nurses  
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27. Lidgren 
et al. (2007) 
(43) 
Sweden 
EBC & MBC states: 
First year after primary BC (state P) 
EQ-5D (n-72) 
 
TTO (n=69) 
 
 
State P with adjuvant chemotherapy:  
EQ-5D (n=23) 
TTO (n=22) 
 
State P with adjuvant hormone therapy: 
EQ-5D (n=17) 
TTO (n=17) 
 
First year after recurrence (State R): 
EQ-5D (n=21) 
 
TTO (n=18) 
 
 
State R with adjuvant chemotherapy: 
EQ-5D (n=7) 
TTO (n=5) 
 
State R with adjuvant hormone therapy;  
EQ-5D (n=4) 
TTO (n=4) 
 
Second and following years after primary 
BC or recurrence (State S) 
EQ-5D (n=177) 
 
TTO (n=178) 
 
Mean (95% CI) 
 
0.696 (0.634-0.747). Median 
0.725. Min 0 Max 1.  
0.901 (0.848-0.935). Median 1. 
Min 0.1. Max 1 
 
 
0.620 (0.509-0.697)  
0.886 (0.801-0.943) 
 
 
0.744 (0.573-0.841)  
0.891 (0.699-0.955) 
 
 
0.779 (0.700-0.849) Median 
0.725. Min 0.296. Max 1.  
0.842 (0.733-0.926) Median 
0.973. Min 0.5. Max 1 
 
 
0.767 (0.573-0.841).  
0.856 (0.656-1) 
 
 
0.816 (0.729-0.963).  
0.861 (0.620-0.991). 
 
 
 
0.779 (0.745-0.811) Median 
0.796. Min 0. Max 1.  
0.889 (0.860-0.913) Median 1. 
Min 0. Max 1 
EQ-5D (UK tariff) 
 
EQ-5D VAS. Anchored 
at worst imaginable 
health-best imaginable. 
 
TTO based on 10 years 
of live in current health 
state and full health. 
 
Negative EQ-5D values 
were set to zero, but 
only 3 patients and 
impact negligible.  
361 BC patients 
from outpatient 
clinic with 
previous diagnosis 
of BC at 
Karolinska 
University 
Hospital, Solna, 
Sweden.  
 
345 patients had 
data on disease 
state from 
Stockholm 
Oncology Centre.  
 
335 completed 
EQ-5D and VAS  
326 completed 
TT0  
 
This study may be p  
up more severe non-
metastatic patients si  
they are more likely  
attend outpatient clin  
 
For metastatic 
patients may be 
higher HRQOL 
because no 
inpatients are 
included – this 
excludes those 
with complications 
EQ-5D 
correlates 
0.65 with the 
VAS. 
 
Impact is 
mostly on 
dimensions 4 
(pain and 
discomfort) & 
5 (anxiety and 
depression). 
 
Moderate or 
severe pain 
reported by 
52% in State 
R, 71% in 
State P, 74% 
in State M  
 
TTO sig. 
higher than 
EQ-5D for all 
states other 
than R. 
Correlation 
was 0.44. 
 
Although 
TTO question 
refers to 'in 
your current 
health state' 
many may 
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State S with adjuvant hormone therapy: 
EQ-5D (n=79) 
TTO (n=76) 
 
Metastatic disease (State M).  
EQ-5D (n=65) 
 
TTO (n=61) 
 
 
State M with adjuvant chemotherapy: 
EQ-5D (n=38) 
TTO (n=35) 
 
State M with hormone therapy: 
EQ-5D (n=16) 
TTO (n=17) 
 
 
The lower than population values levels in state 
S suggest permanent negative effect of BC. 
 
Note that EQ-5D value for first year after 
primary is lower than that for metastatic 
disease. 
 
0.824 (0.785-0.857).  
0.934 (0.890-0.960) 
 
 
0.685 (0.620-0.735). Median 
0.725. Min 0.093. Max 1.  
0.820 (0.760-0.874). Median 
0.850. Min 0.110. Max 1. 
 
 
0.692 (0.611-0.746).  
0.776 (0.695-0.8411) 
 
 
0.648 (0.513-0.765).  
0.863 (0.737-0.8940) 
 
and end stage of 
disease. 
 
Mean age 57 
(range 28-93) 
have 
perceived this 
as temporary. 
 
Those with 
different TTO 
to EQ-5D 
values 
reported they 
did not want 
to shorten 
their time 
with their 
family. 
 
The greater 
values in state 
R than P may 
be due to a 
coping effect 
and knowing 
what to 
expect. 
 
 
28. Lloyd et 
al. (2006) 
(44) 
UK 
MBC states: 
Utility values for a 38.2 year old. 
Base state – stable metastatic disease with no 
toxicity 
Treatment response 
Disease progression 
Febrile neutropenia 
Diarrhoea and vomiting 
Hand-foot syndrome 
 
 
0.715  
 
+0.075 
-0.272 
-0.150 
-0.103 
-0.116 
15 health states 
identified from 
the literature and 
developed by 
interviews and 
focus groups with 
experts in BC 
none of which 
specified breast 
Recruited from 
Greater London 
through 
advertisements in 
the local 
newspapers and 
existing UBC 
database of willing 
participants. 
Males rated 
disease 
progression as 
a greater 
decrement to 
utility than 
females. 
 
Age of 
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Stomatitis  
Fatigue 
Hair loss 
 
Coefficients from the log mixed model analysis 
are presented along with standard errors.  
-0.151 
-0.115 
-0.114 
cancer. 
 
Initially all states 
(including own, death, 
full health and worst 
health) rated using VAS 
 
SG, living in health 
state for 10 years with 
certainty versus 
probability of full health 
or the worst health state. 
 
Worst state is valued 
against dead, allowing 
for the possibility of 
being worse than dead. 
 
Utility states 
recalibrated to 0 (dead) 
1 (full health). 
 
SG valuations analysed 
using a mixed model 
analysis to determine 
the change in utility 
score associated from 
moving between stages 
of disease and from no 
toxicity to one of the 
toxicities. Raw data 
were transformed using 
a logistic 
transformation. 
Negative scores were 
 
Respondents 
complete some 
anchor states and 
half the remaining 
states, since 18 
states considered 
too many. 
 
100 completed 
interview. 50% 
female. Mean age 
40.16 (sd 13.59) 
participants 
had a positive 
correlation 
with utility 
values. Older 
participants 
may be more 
risk averse, or 
perceive less 
of a departure 
from their 
current state. 
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changed to 0.02 to 
obtain a normal 
distribution for the 
standard regression 
model. Age is included 
in the analysis.  
 
29. Lovrics 
et al. (2008) 
(65)  
Canada 
EBC states: 
Initial consultation (n=85) 
Post PET (n=74) 
Post Op (n=83) 
3 month (n=80) 
6 month (n=84) 
12 month (n=73) 
18 month (n=67) 
24 month (n=72) 
 
Normative data from CCHS 1.1 (2000-2001) 
n=75,000 
Mean (SD)  
0.74 (0.26) 
0.76 (0.26) 
0.49 (0.33) 
0.73 (0.27) 
0.73 (0.28) 
0.79 (0.23) 
0.81 (0.22) 
0.78 (0.24) 
 
0.87 (0.21) 
HUI3  Candidates for 
BCS at Joseph’s 
Healthcare and 
Hamilton Health 
Sciences.  
Age mean 55.2 
 
30. Mansel 
et al. (2007) 
(28) 
UK 
EBC states: 
Disease-free state, no adverse events 
Common adverse events (tamoxifen) 
Common adverse events (anastrozole) 
Vaginal bleeding 
Endometrial cancer 
Wrist fracture 
New contralateral BC 
Local/regional recurrence 
Deep vein thromboembolism 
Pulmonary embolism 
Spinal fracture 
Hip fracture 
Hormonal therapy for distant recurrence 
Mean (SD) 
0.989 (0.010) 
0.970 (0.041) 
0.962 (0.055) 
0.933 (0.099) 
0.913 (0.101) 
0.916 (0.099) 
0.914 (0.097) 
0.911 (0.098) 
0.922 (0.107) 
0.890 (0.166) 
0.894 (0.189) 
0.858 (0.199) 
0.882 (0.105) 
Chained SG.  
Anchored at worst and 
perfect health, then 
rescaled to death and 
perfect health. 
 
26 UK patients 
with early or 
advanced BC 
Mean age 68 
years. Most 
patients had HR+ 
node-negative 
disease and were 
presently receiving 
tamoxifen; a 
minor proportion 
was receiving 
anastrozole (no 
patient was 
Table 3 
showing 
mean utility 
scores refers 
to n=23. 
(Data in 
Sorenson et 
al. is only 
based on 23 
UK patients). 
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Chemotherapy for distant recurrence 
Current health 
Hysterectomy 
0.710 (0.254) 
0.933 (0.069) 
0.899 (0.101) 
receiving 
treatment within 
the ATAC trial). 
31. 
McLachlan 
et al. (1999) 
(45) 
Canada 
MBC states: 
Metastatic BC, baseline before chemotherapy 
Median (IQR) 
0.92 (0.79-1.0) 
TTO using 12 months, 
on own health. 
Anchored at death-
perfect health. 
32 patients with 
MBC presenting 
for third line 
chemotherapy, in 
Ontario. Median 
age 56 (for the full 
n=35 sample) 
(range 38-77) 
Scores for 
QLQ-c30 
correlated 
poorly with 
utility scores. 
32. Milne et 
al. (2006) 
(46) 
New 
Zealand 
MBC states: 
State 1. Bone metastases receiving hormonal 
therapy. 
 VAS (n=46) 
  
 TTO (n=40) 
  
 EQ-5D NZ (n=50) 
  
 EQ-5D UK (n=50) 
 
 
State 2. Severe bone pain requiring 
radiotherapy 
 VAS (n=46) 
  
 TTO (n=45) 
  
 EQ-5D NZ (n=50) 
  
 EQ-5D UK (n=50) 
 
 
 
 
Mean 0.54 (95%CI 0.48-0.59)  
Med 0.53 IQR (0.4-0.68) 
Mean 0.65 (95%CI 0.57-0.73)  
Med 0.71 IQR (0.46-0.88) 
Mean 0.54 (95%CI 0.51-0.58)  
Med 0.61 IQR (0.54-0.61) 
Mean 0.60 (95%CI 0.54-0.65)  
Med 0.69 IQR (0.59-0.69) 
 
 
 
Mean 0.35 (95%CI 0.30-0.40)  
Med 0.32 IQR (0.25-0.48) 
Mean 0.45 (95%CI 0.37-0.54)  
Med 0.46 IQR (0.21-0.67) 
Mean 0.31 (95%CI 0.27-0.35)  
Med 0.23 IQR (0.16-0.46) 
Mean 0.25 (95%CI 0.18-0.33)  
Med 0.19 IQR (-0.02-0.52) 
VAS. Anchored from 
worst to best 
imaginable, then 
normalised to dead-best 
imaginable. 
 
Allowing SWD. 
 
Positioned states on 
EQ-5D. Both using UK 
and NZ tariffs. 
 
TTO used ping pong 
method on living 
additional 12 months. 
Anchored at dead and 
full health. 
50 women from 
Auckland.  
Mean age 46 
(range 25-69) 
Health states 
represented 
by case 
descriptions 
developed by 
oncology 
professionals. 
 
NB: Original 
paper has the 
methods mis-
labelled on 
the data table 
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State 3. Moderate to severe hypercalcemia 
 VAS (n=46) 
  
 TTO (n=50) 
  
 EQ-5D NZ (n=50) 
  
 EQ-5D UK (n=50) 
 
 
State 4. Chemotherapy rather than hormonal 
therapy for advanced cancer not receiving 
radiotherapy for bone pain.  
 VAS (n=46) 
  
 TTO (n=47) 
  
 EQ-5D NZ (n=50) 
  
 EQ-5D UK (n=50) 
 
 
 
Mean 0.13 (95%CI 0.09-0.17)  
Med 0.12 IQR (0.05-0.20) 
Mean -0.17 (95%CI -.29- -.05).  
Med -0.08 IQR (-0.54-0.02) 
Mean -0.05 (95%CI -.07- -.03).  
Med -0.08 IQR (-0.08-0.01) 
Mean -0.52 (95%CI -.56- -.48).  
Med -0.59 IQR (-0.59- -0.43) 
 
 
 
 
Mean 0.46 (95%CI 0.41-0.51) 
Med 0.46 IQR (0.36-0.55) 
Mean 0.49 (95%CI 0.40-0.57)  
Med 0.58 IQR (0.21-0.71) 
Mean 0.48 (95%CI 0.43-0.53)  
Med 0.54 IQR (0.31-0.61) 
Mean 0.51 (95%CI 0.43-0.59)  
Med 0.62 IQR (0.26-0.69) 
33. 
Namjoshi et 
al. (1998) 
(66) 
USA 
 
Abstract  
EBC states: 
FACT-G dimension scores explained 26% of 
variation in SG, 39% of HUI, 50% of VAS, and 
47% of EQ-5D 
 
FLIC dimension scores explained 42% of 
variation in the SG, 43% of HUI, 54% of VAS 
and 56% of EQ-5D 
Mean (SD) 
SG 93.3 (11.5) 
HUI3 84.6 (16.8) 
VAS 86.6 (12.6) 
EQ-5D 87.4 (10.8) 
 
 
SG 
HUI3 
VAS 
EQ-5D 
75 BC patients. 
Mean age 60. 
96% had either 
stage I or II 
disease 
Studies 
compares to 
FACT-G and 
FLIC 
 
 
34. Ossa et 
al. (2007) 
(84) 
Chemotherapy related anaemia 
No-anaemia 
Mild anaemia 
Mean (SD), ratio 
0.86 (0.14), 1 
0.78 (0.17), 0.91 
TTO.  
Study used TTO 
anchored at 0 (dead) 
110 members of 
the public of 
which 4 did not 
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Moderate anaemia 
Severe anaemia 
0.61 (0.21), 0.72 
0.48 (0.21), 0.56 
and 1 (ideal health for 
the no-anaemia state). 
Then assumed an EQ-
5D value (21122) or 
0.86 for the no-anaemia 
state.  
trade leaving 106 
with a mean age of 
45.  
35. Pickard 
et al. (2007) 
(85) and 
personal 
comm. 
 
USA 
Advanced BC 
Post chemotherapy 
 
Mean (SD) 
0.667 (0.25) 
 
EQ-5D UK tariff 52 advanced 
breast cancer 
patients (stage 3/4) 
who had received 
chemotherapy (at 
least 2 cycles or 
for at least 1 
month). Mean age 
52 (SD=11) 
 
36. Polsky 
et al. (2002) 
(67) 
USA 
EBC states: 
5 months after surgery. VAS unadjusted. 
Choice 
5 months after surgery. VAS unadjusted. No 
Choice 
5 months after surgery. VAS adjusted for 
covariates. Choice 
5 months after surgery. VAS adjusted for 
covariates. No Choice 
 
Choice of mastectomy, BCS with radiation, or 
BCS only. 
 
Values for 1 year and 2 years after surgery are 
presented graphically only. 
 
 
Mean (SD) 
VAS: 78.8 (15.9), HUI: 82.5 
(21.4) 
VAS: 74.8 (17.1), HUI: 76.8 
(27.3) 
VAS:  78.7, HUI: 81.9 
 
VAS:  75.3, HUI: 78.3 
 
 
EQ-VAS  
 
Health Utilities Index 
Mark 3 (HUI3) 
 
3-5 years after surgery 
Women with 
breast carcinoma 
identified from 
inpatient and 
outpatient 
pathology records 
and surgical logs 
at 29 hospitals. 
Eligibility:  
patients for whom 
breast 
conservation and 
mastectomy were 
considered 
clinically 
equivalent; 
community 
dwelling, 67 years 
Age given as 
frequencies. 
(estimated at 
Choice: 73.8, 
Non choice 
75.5) 
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of age or older, 
and had 
histologically 
confirmed primary 
T1 or T2; N0, N1, 
or NX; and M0 
invasive breast 
carcinoma. 
Women with 
DCIS, bilateral 
carcinoma, or 
multicentricity 
were excluded. 
n = 683 for VAS 
n= 661 for HUI 
Choice = n=566 
No choice = 
n=117 
 
37. Prescott 
et al. (2007) 
(68) 
 
UK 
PRIME 
trial. 
EMC states: 
Radiotherapy group (n=102) 
Baseline 
3.5 months 
9 months 
15 months 
 
No-radiotherapy group (n=101) 
Baseline 
3.5 months 
9 months 
15 months 
 
Mean (95%CI) 
 
0.77 (0.73-0.80) 
0.78 (0.74-0.81) 
0.76 (0.71-0.81) 
0.74 (0.70-0.78) 
 
 
0.74 (0.70-0.77) 
0.76 (0.73-0.79) 
0.72 (0.68-0.76) 
0.73 (0.69-0.77) 
EQ-5D UK tariff. Low risk axillary 
node negative 
breast cancer 
treated with BCS 
and endocrine 
therapy. Inclusion: 
Age 65+, low risk 
of local 
recurrence.  
 
Age radiotherapy 
(n=127) 72.3 (5.0) 
No-radiotherapy 
(n=128) 72.8 (5.2) 
Trial also 
contains the 
EORTC and 
is used for a 
mapping 
study. 
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38. 
Rijnsburger 
et al. (2004) 
(21) 
Netherlands 
Screening states: 
2 months prior to screening (n=329) 
day of screening (n=316 ) 
1-4 weeks post screening (n=288) 
Mean  
EQ-5D 0.88, EQ-VAS 0.819 
EQ-VAS 0.790 
EQ-5D 0.88, EQ-VAS 0.807 
EQ-5D (UK tariff) 
EQ-VAS 
Women under 
surveillance at 
cancer clinic and 
women joining 
surveillance for 
the first time. 
Exclusion: evident 
symptoms 
suspicious for BC 
or previous BC. 
Mean age: 40.9 
 
39. Sackett 
and 
Torrance 
(1978) (24) 
Canada 
EBC states: 
Mastectomy for BC, 8 years 
Mastectomy for injury, 8 years. 
 
Also found that for other states surveyed mean 
daily health state utility fell sharply as the 
duration (3 months, 8 years, life) of the health 
state increases.  
 
0.48 (se 0.044) 
0.63 (se 0.038) 
TTO. Anchored: death 
to perfect health 
58 community 
sample from 
Ontario, 41-79 
year old females. 
 
40. 
Schleinitz et 
al. (2006) 
(47) 
USA 
EBC & MBC states: 
Stage I 
Stage II 
Stage III 
Stage IV ER+ 
State IV ER-  
Chemotherapy (TTO) 
Hormonal therapy (TTO) 
Radiation therapy (TTO) 
 
Stage I 
Stage II 
Stage III 
Stage IV ER- 
 
Med 0.91 Range (0.5-1) 
Med 0.75 Range (0.26-0.99) 
Med 0.51 Range (0.25-0.94) 
Med 0.36 Range (0-0.75) 
Med 0.40 Range (0-0.79)  
Med 0.50 Range (0-0.92) 
Med 0.58 Range (0-1) 
Med 0.83 Range (0.1-1) 
 
Mean 0.68 (95%CI +/-0.06) 
Mean 0.61 (95%CI +/-0.06) 
Mean 0.56 (95%CI +/-0.06) 
Mean 0.42 (95%CI +/-0.06) 
8 health states 
developed via team of 
BC specialists, included 
5 states of disease based 
on the TNM 
classification system 
(state I, II, III, IV 
receptor positive, IV 
receptor negative) 
3 treatment modalities 
(chemotherapy, 
radiotherapy and 
hormonal therapy). 
 
Convenience 
sample of socio-
demographically 
diverse women, 
over 25 years from 
primary care 
clinics and the 
community. 
Women currently 
undergoing 
treatment for BC 
were excluded. 
 
N= 156 
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State IV ER+  
Chemotherapy (TTO) 
Hormonal therapy (TTO) 
Radiation therapy (TTO) 
 
Those with income < $25,000 had significantly 
lower utilities for Stage I, II and III, and for 
Hormonal treatment. 
 
Single people had significantly lower utilities 
for all the treatment states (chemotherapy, 
hormonal and radiation). 
 
Those with above high school education had 
significantly higher utilities for states I, II and 
IV.  
 
Valuations varied significantly by race. Whites 
gave the highest valuation for Stage I, II, II and 
hormonal treatment (whites value stage I at 
0.79, blacks valued at 0.56). 
 
Those with BC in the family gave a higher 
valuation for stage II, other differences non-
significant. 
 
No significant differences by age.  
Mean 0.41 (95%CI +/-0.06) 
Mean 0.48 (95%CI +/-0.06) 
Mean 0.54 (95%CI +/-0.07) 
Mean 0.61 (95%CI +/-0.07) 
SG. Anchored at death 
and best imaginable 
health. Using 10 years 
of best imaginable 
health, and bisection 
method.  
 
Also elicited treatment 
utilities using TTO, 
based on 1 year 
description of treatment 
and recovery.  
49% had family 
member with 
history of BC 
61% post 
menopausal 
46% >= 50 
41. Shih et 
al. (2006) 
(37) 
China 
BC general: Mean (SD) 
0.81 (0.12) 
SF-36 in Chinese, using 
algorithm to translate 
into the SF-6D 
N=59 inpatient 
and outpatients at 
a cancer hospital, 
over 18 with a 
pathological 
diagnosis of breast 
cancer. 
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42. Simons  
(2007) (48) 
USA 
 
Abstract 
Some data 
kindly 
given by 
Rob Simons 
at Global 
Health 
Economics 
and 
Outcomes 
Research, 
NJ, USA 
ABC states: 
VAS  
Baseline ABC 
Treatment response 
No treatment response but no progression 
Disease progression 
 
SG  
Baseline ABC 
Treatment response 
No treatment response but no progression 
Disease progression 
Health state of toxicity 
 
Mean (SD) (range) 
 
52.65 (18.06) (9.0–85.0) 
72.64 (14.38) (16.0-95.0) 
59.22 (16.51) (12.0-97.0) 
34.32 (15.91) (5.0-70.0) 
 
 
0.64 (0.18) (0.15-0.95) 
0.75 (0.16) (0.25-0.95) 
0.67 (0.18) (0.25-0.95) 
0.51 (0.20) (-0.05-0.95) 
0.34 (0.26) (0.05-0.95) 
 
FACT-B QOL data 
used to compare health 
narratives. Toxicities 
described separately. 
 
VAS 
SG. Anchored at dead 
and perfect health. 
N=100 peri-post 
menopausal 
women. 
 
Mean age 55.76, 
range 40-85 
63% post 
menopausal, 11% 
had BC previously 
16% another type 
of cancer 
 
Those who 
had 
experienced 
BC before 
gave sig. 
higher 
valuations. 
43. 
Sorenson et 
al. (2004) 
(29) 
 
Abstract  
 
Also taken 
from 
Locker et 
al. (2007) 
(86) 
 
Also taken 
from 
presentation 
(same title) 
kindly 
EBC, MBC and side effects 
POOLED SAMPLE (n=67) 
Disease free, no adverse events  
Adverse events No. 1 (weight gain, hot flushes, 
vaginal discharge)  
Adverse events No. 2 (weight gain, joint pain, 
hot flushes, vaginal discharge) 
Endometrial cancer 
Local/Regional Recurrence 
DVT 
Hip fracture 
Hormonal Tx/Distant cancer 
Chemotherapy / Distant cancer 
Current health 
 
USA sample (n=44): 
Disease-free state, no adverse events  
Common adverse events (tamoxifen)  
Mean (SD) 
 
0.974 (0.033) 
0.963 ( 0.042) 
 
0.959 (0.50) 
 
0.865 (0.198) 
0.816 (0.244) 
0.796 (0.250) 
0.730 (0.290) 
0.724 (0.289) 
0.432 (0.392) 
0.907 (0.129) 
 
 
0.965 
0.959 
Chained SG. Anchored 
at worst to perfect 
health. Rescaled to 
dead-perfect health. 
 
14 states assessed 
including own health 
Women aged 55–
70 years in the UK 
and the USA with 
a history of stage 
one or two 
operable EBC and 
experience with 
adjuvant hormonal 
therapy. 
 
UK = 23 
USA = 44 
Pooled sample, 
mean age 67.8 
years. 51% with 
arthritis 
USA sample mean 
age 67.5 
The worst 
health state 
very different 
valuation 
between US 
and UK 
samples. 
 
More 
chemotherapy 
in the US 
within the 
sample. 
 
Pooled data 
not included 
since included 
separately via 
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given by 
Sonja 
Sorensen, at 
MEDTAP 
Int. 
 
USA and 
UK 
 
UK values 
also 
reported in 
Mansel et 
al. (2007) 
(28) 
Common adverse events (anastrozole)  
Vaginal bleeding  
Wrist fracture  
Local/regional recurrence  
Hormonal therapy for distant recurrence  
Endometrial cancer  
Spine fracture  
New contralateral BC  
Deep vein thrombosis  
Pulmonary embolism  
Hip fracture  
Chemotherapy for distant recurrence  
Current health 
 
0.958 
0.926 
0.852 
0.766 
0.642 
0.839 
0.751 
0.702 
0.729 
0.741 
0.664 
0.288  
0.893 (0.15) 
 
UK (Mansel 
et al. (2007) 
(28) and the 
US data 
reported in 
the abstract. 
44. 
Stratmann-
Schoene et 
al. (2006) 
(35) 
Germany 
General BC state: 
Own health state: 
VAS 
Predicted by SF-12 model 
Mean (SD) 
 
0.724 (.176) (95%CI .697-.744) 
0.506 (.237) (95%CI .475-.537)  
VAS, anchored at worst 
imaginable health state 
– best imaginable health 
state.  
SF-12 
 
Each respondent valued 
the best and worst 
health state which can 
be described by the SF-
12. All valuations were 
then standardized on 
this worst health state 
scale by linear 
transformation. 
 
Standardization on the 
‘dead’ health state scale 
was not carried out. 
N=199 
Women who had 
received surgical 
treatment for BC.  
 
Postal survey. 
Mean age 56.4. 
 
Interviews. Mean 
age 60.6.  
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45. Sullivan 
et al. (2005) 
(32) 
USA 
General BC state: 
 
Marginal decrement in EQ-5D score after 
controlling for age, co-morbidity, gender, race, 
ethnicity, income and education.  
 
 
Cancer of the breast (n=236; mean age 64) 
 
 
Unadjusted  Mean EQ-5D 0.810 
25% 0.768 
50% 0.827 
75% 1.000  
 
Disutility of condition from the 
regression model (adjusted) 
-0.0150 (se 0.0010) 
EQ-5D algorithm based 
on US community 
preferences. 
 
OLS, Tobit (since 46% 
of MEPS sample rated 
themselves as 11111), 
and censored least 
absolute deviations 
estimated (CLAD) 
robust alternative to the 
maximum likelihood 
estimation for the Tobit 
model, which does not 
require normally 
distributed errors. 
Evidence of 
heteroscedasticity and 
nonnormality of the 
residuals, hence Tobit 
model not reported. 
Medical 
Expenditure Panel 
Survey (MEPS), 
diagnoses based 
on ICD-9 codes. 
Contains the EQ-
5D.  
 
Research uses 
pooled 2000, 2001 
and 2002 data 
giving 38,678 
unique individuals 
(>= 18) with valid 
EQ-5D scores.  
 
 
46. Walker 
et al. (2006) 
(49) 
UK 
 
Abstract  
EBC & MBC states: 
Early disease free survival (< 5 years) 
Metastatic disease 
Later disease free survival (> 5 years) 
Contra-lateral primary disease 
Loco-regional recurrence 
Mean 
VAS: 0.697, SG: 0.75 
VAS: 0.225, SG: 0.48 
SG: 0.85 
SG: 0.58 
SG: 0.57 
VAS.  
SG.  
N=100 of general 
UK public 
 
47. 
Wolowacz 
et al. (2008) 
(69) 
 
20 
EBC node positive: 
Remission (n=929) 
Mean (variance) 
0.79 (0.016) 
Data collected in trial 
BCIRG001. EORTC 
QLQ-C30 mapped onto 
the EQ-5D using 
algorithm from Kind 
(2005). UK tariff. 
Patients who had 
completed 
chemotherapy and 
had not 
experienced a 
relapse. 
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countries.  Inclusion: Age 18-
70, had a score on 
the Karnofsky 
performance 
scale of 80% or 
more, and had 
undergone 
primary surgery 
with axillary-node 
dissection. Median 
age for the original 
sample for 
BCIRG001 was 
49.  
48. Yabroff 
et al. (2004) 
(31) 
USA 
General BC state: 
BC 
Non cancer control  
Mean (95% CI) 
0.75 (0.73-0.78) 
0.80 (0.80-0.81) 
Applies HALex utility 
weights to their self-
reported health 
(excellent, very good, 
good, fair, or poor) and 
reported limitations in 
usual activities. HALex 
utility weights were 
obtained from the 2000 
Medical Expenditure 
Panel Survey by 
mapping responses to 
self-rated health and 
limitations in usual 
activities questions to 
independently obtained 
utility measures from 
the EQ-5D. USA TTO 
tariff. 
2000 Medical 
Expenditure Panel 
Survey  
 
BC n= 339 
Non cancer 
controls n= 5468 
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49. Yabroff 
et al (2007) 
(34) 
USA 
General BC state 
Initial (within 1 year of diagnosis) (n=389) 
Continuing (n=381) 
Last year of life (n=150) 
 
Non-cancer control (matched by age, education 
and gender) 
Initial (within 1 year of diagnosis) (n=1945) 
Continuing (n=1905) 
Last year of life (n=150) 
 
Mean (95% CI) 
0.78 (0.76-0.80) 
0.81 (0.79-0.82) 
0.64 (0.61-0.68) 
 
 
 
0.85 (0.84-0.86) 
0.85 (0.84-0.85) 
0.73 (0.69-0.76) 
As above. 1986-1994 
National Health 
Interview Survey. 
 
 
 
 
 
Table B.2: Studies which are not included but have accessible utility values 
 
Study Health state description Health state value How valued Who valued Comments & reason 
for exclusion. 
1. Ashby et 
al. (1994) 
(87) 
UK 
5 states. All involve diagnosis 1 year 
previously and no evidence of cancer 
returning. No longer experiencing any side 
effects of drugs. States vary on 
mastectomy/lumpectomy, supportive partner, 
sexual relationships, concern for recurrence, 
confidence, concern about appearance, friends 
and family, and interests. 
 
W: Lumpectomy, occasional concern of 
recurrence, confident in control, enjoys friends, 
interests as before, partner supportive, sexual 
relations good. 
Study shows values 
disaggregated by age, 
gender and respondent 
group (e.g. patient, GP etc.) 
 
 
 
 
 
Mean 0.784 Med. 0.850 
(IQR 0.650-0.950)  
 
 
TTO using 20, 30, 40 
or 50 years depending 
upon age.  
Anchors: Death - 
healthy 
 
Assumed all states 
better than dead. 
49 nurses,  
20 hospital doctors,  
24 GPs,  
28 university staff 
from Brunel 
university,  
17 breast cancer 
patients 1 year 
previous, non 
recurring. 
 
Total sample N=138. 
 
Not included because 
social conditions are 
included within the 
vignettes. 
 
BC patients rated 
mastectomy higher 
than non-patients. 
 
Worst 3 states are 
rated higher by the 
eldest group. 
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L: Mastectomy, with plastic surgery to make a 
new breast, occasional concern of recurrence, 
confident in control, enjoys friends, interests as 
before, partner supportive, sexual relations 
good. 
 
P: Mastectomy, occasional concern of 
recurrence, confident in control, occasional 
concern for appearance, enjoys friends, 
interests as before, partner supportive, sexual 
relations good. 
 
K: Lumpectomy, some swelling and stiffness 
in arm restricting movement, engulfed by fear 
of recurrence and death, not able to go out, 
tearful, not sleeping well, partner not 
supportive, sexual relations declined.  
 
T: Mastectomy, some swelling and stiffness in 
the arm restricting movement, engulfed by 
fears of recurrence and death, not able to go 
out, tearful, not sleeping well, very sensitive 
about appearance, partner not supportive, 
sexual relations declined.  
 
Mean 0.714 Med. 0.850 
(IQR 0.550-0.950) 
 
 
 
 
Mean 0.703 Med. 0.850 
(IQR 0.550-0.950) 
 
 
 
 
Mean 0.284 Med. 0.125 
(IQR 0.000-0.550) 
 
 
 
 
Mean 0.257 Med. 0.050 
(IQR 0.000-0.450). 
Age of respondents 
given as frequency 
data. 
Mean values suggest 
preference order of 
lumpectomy, 
mastectomy with 
reconstruction, then 
mastectomy, although 
median values are the 
same for each of these 
states. 
 
A large drop in values 
arises when mental 
health states and 
social support 
deteriorates. 
 
2. Brown et 
al. (2001) 
(88) 
UK 
MBC states:  
Start of second-line therapy 
Partial/complete response 
Stable disease 
Progressive disease 
Terminal disease 
PN with partial/complete response 
Severe oedema with partial/complete response 
Severe skin condition with partial/complete 
Mean (SD) 
0.64 (0.15) 
0.84 (0.12) 
0.62 (0.22) 
0.33 (0.24) 
0.13 (0.12) 
0.62 (0.16) 
0.78 (0.15) 
0.56 
SG 
Respondents valued a 
core of 8 states plus 
an additional random 
5 states from the full 
23 states. 
 
Marker states worst 
possible and best 
30 oncology nurses in 
the UK.  
 
Sample age not stated. 
Not included because 
values are reported 
combined with other 
country values in 
Hutton et al. (1996) 
(41) (except those 
which are estimated 
from other toxicities). 
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response (estimated from other toxicities) 
Febrile neutropenia and hospitalised 
Infection without hospitalisation 
 
Severe skin condition, and infection not 
included since these were estimated from other 
toxicities.  
 
0.24 (0.12) 
0.48 
possible were also 
included. 
3. Brown 
and Hutton 
(1998) (51) 
USA 
MBC states:  
At start of second-line chemotherapy 
Partial / full response (PR) 
Stable disease (SD) 
Progressive disease (PD) 
Terminal disease 
PN + PR 
PN + SD 
Severe edema + PR 
Sever edema + SD 
Severe skin condition 
Cardiac toxicity 
Febrile neutropenia with hospitalisation 
Infection no hospitalisation 
 
Mean. US: n=29, Av of 6 
countries 
US: 0.69   Av: 0.64  
US: 0.84   Av: 0.81 
US: 0.70   Av: 0.65 
US: 0.49   Av: 0.39 
US: 0.23   Av: 0.16  
US: 0.58   Av: 0.56 
US: 0.41   Av: 0.44 
US: 0.82   Av: 0.76 
US: 0.68   Av: 0.62 
US: 0.65   Av: 0.56 
US: 0.54   Av: 0.59 
US: 0.42   Av: 0.30 
US: 0.56   Av: 0.60  
 
SG. Anchored dead - 
perfect health. 
US oncology nurses 
(n=29). Mean age 39. 
25-30 nurses each 
from Germany, Italy, 
Netherlands, Spain 
and UK also used.  
 
4. Brown et 
al. (2005) 
(89) & 
Brown et al. 
(2004) (90) 
UK 
Abstract  
Reported in Mansel et al. (2007) (28) & 
Sorensen et al. (2004) (91) 
 SG. Anchored dead - 
perfect health. 
 Not included because 
values reported in 
Mansel et al. (2007) 
(28) 
5. Buxton et 
al. (1987) 
 
W: Lumpectomy, good physical, good mental 
Mean (95% CI) 
0.722 (0.699-0.775) 
TTO using 20, 30, 40 
or 50 years depending 
N=121 
Nurses, hospital 
Not included because 
social conditions are 
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(92) 
UK 
 
L: Mastectomy, good physical, good mental 
P: Mastectomy, no new breast, as L but 
occasional concern for appearance 
K: Lumpectomy, poor physical, poor mental 
T: Mastectomy, poor physical, poor mental 
0.695 (0.640-0.750) 
0.680 (0.623-0.737) 
 
0.271 (0.212-0.330) 
0.237 (0.182-0.292) 
upon age.  
Anchors: Death - 
healthy 
 
Using ping pong 
method. 
 
Assumed all states 
better than dead. 
doctors and GPs and 
university staff. 
included within the 
vignettes. 
 
Data also reported in 
Ashby et al. (2004). 
This data does not 
include the 17 breast 
cancer patients 
included in Ashby et 
al. (2004). However, 
this study does show 
confidence intervals. 
 
The values are lower 
for all states 
compared to the 
sample that includes 
17 BC patients.  
6. Carter et 
al. (1998) 
(93) 
Local recurrence 
Mastectomy 
Metastatic disease 
Radiation* 
Reversible complication* 
Tamoxifen* 
Endometrial CA 
 
*Utilities become 1.0 upon completion of 
treatment or recovery from complication.  
0.8 
0.99 
0.50 
0.99 
0.99 
0.999 
0.95 
 
Not stated whether these 
are means or medians of 
values from individual 
professionals or a group 
consensus. 
‘Basic Reference 
Gamble’ (SG)  
Anchors: dead – 
absence of disease. 
 
Patients under 
observation with no 
evidence of disease 
were assigned an 
initial utility of 1, and 
0 at the time of death.  
Panel of health care 
professionals familiar 
with Basic Reference 
Gamble (SG) and BC.  
Sample size & age not 
stated. 
Not included because 
no sample size or SD 
included. 
7. Franic et 
al. (2003) 
Post-chemotherapy nausea and vomiting, 
PCNV 
Mean (SD)  
3 days v Rest of Life 
VAS. Anchored 
initially at least to 
Convenience sample 
of 18 women aged 22-
Not included because 
the PCNV states are 
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(76) 
USA 
 
VAS 3 days vs rest of life.  
Own health 
Complete alleviation 
Partial alleviation 
No alleviation 
 
SG 3 days v rest of life. 
Own health 
Complete alleviation 
Partial alleviation 
No alleviation 
 
0.944 (.069) v 0.939 (.073) 
0.741 (.115) v 0.676 (.225) 
0.490 (.165) v 0.307 (.215) 
0.276 (.164) v 0.136 (.135) 
 
 
0.994 (.019) v 0.985 (.032) 
0.968 (.058) v 0.927 (.066) 
0.942 (.074) v 0.810 (.141) 
0.866 (.138) v 0.644 (.243) 
 
most desirable.  
Rescaled to death and 
perfect health. 
 
SG top-down titration 
method. Anchored 
death - perfect health. 
 
Both methods allowed 
SWD. 
 
50 with no history of 
breast cancer or 
chemotherapy.  
 
Mean age 28. 
general cancer states 
rather than 
specifically related to 
breast cancer. 
 
High percentage of 
respondents would not 
trade for the 3 day 
condition in SG. 
8. Franic et 
al. (2005) 
(94) 
 
USA 
P1: Complete alleviation of PCNV (no nausea 
and vomiting episodes, varied diet, not 
depressed or anxious, able to work and 
socialize) for 3 days versus partial alleviation 
 
P2: Partially alleviation of PCNV (ongoing 
nausea and one vomiting episode per day, 
somewhat depressed and anxious, unable to 
work, and limited social activity) for 3 days, 
versus no alleviation 
 
P3: Complete alleviation of PCNV (ongoing 
nausea and two vomiting episodes per day, 
somewhat depressed  and anxious, unable to 
work and declined social activity) for 3 days 
versus no alleviation 
 
C1: Cure (small scar on one breast, arthritis, 
not depressed or anxious, able to work and 
socialize) for indefinite period versus treatment 
(small scar on both breasts, not depressed or 
anxious, able to work, declined social activity) 
QALY gain 0.00035 (SG) 
QALY gain 0.00192 
(VAS) 
 
 
 
QALY gain 0.0007 (SG) 
QALY gain 0.0015 (VAS) 
 
 
 
 
QALY gain 0.0034 (SG) 
QALY gain 0.0107 (VAS) 
 
 
 
 
QALY gain 31.18 (SG) 
QALY gain 26.7 (VAS) 
 
 
VAS. Anchored 
initially at least 
desirable to most 
desirable. Rescaled to 
death and perfect 
health. 
 
Valuation included 
own health, perfect 
health and death 
 
SG. Top down 
titration method. The 
time horizon of 3 days 
was given. 
 
Both VAS and SG 
were compared to 
rankings, participants 
were allowed to 
change them. 
 
119 women, >= 22 
yrs, no prior diagnosis 
of BC or cancer 
requiring treatment.  
 
Mean age 29, 82% 
graduate students. 
Not included because 
comparisons are to 
other conditions not 
perfect health. 
 
In the PCNV study at 
least 20% of 
respondents refused to 
gamble. Respondents 
felt they could tolerate 
anything for 3 days, 
so not worth risking 
death for. 
 
Study also compares 
values to WTP 
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resulting in 12 additional life years 
 
C1: Treatment resulting in additional 12 years 
of life versus recurrence (small scar, depressed 
and anxious, unable to work, social activities 
have ceased) for 2 additional years of life 
 
C3: Cure for an indefinite period versus 
recurrence for 2 additional life years. 
 
 
 
 
QALY gain 9.33 (SG) 
QALY gain 5.73 (VAS) 
 
 
QALY gain 40.5 (SG) 
QALY gain 32.4 (VAS) 
Both methods allowed 
SWD. 
 
 
9. Gerard et 
al. (1993) 
(71) 
Australia 
Early BC states 
Lumpectomy, good physical health otherwise, 
good mental health  
Lumpectomy, poor physical health otherwise, 
poor mental health  
Lumpectomy, recurrence leads to mastectomy, 
good physical health otherwise, poor mental 
health  
Mastectomy, unilateral, good physical health 
otherwise, good mental health  
Mastectomy, unilateral, good physical health 
otherwise, poor mental health 
Mastectomy, unilateral, poor physical health, 
poor mental health  
 
0.75 (n=44 without BC) 
0.77 (104 women) 
0.25 (n= 44 without BC) 
0.31 (104 women) 
0.21 (n=44 without BC), 
0.27 (104 women) 
0.76 (n=44 without BC), 
0.80 (104 women) 
0.28 (n=44 without BC), 
0.33 (104 women) 
0.23 (n=44 without BC), 
0.31 (104 women) 
 
TTO. Anchored at 
dead to good health. 
104 community 
women (aged 45-69) 
with and without BC, 
of which 44 without 
breast cancer, living 
in Sydney 
metropolitan area 
Not included because 
health states are 
difficult to classify 
10. 
Grimison et 
al. (2009) 
(95) 
 
Australia & 
New 
Zealand. 
EBC and MBC states 
 
Advanced Cancer before treatment (n=295) 
EBC trial, before treatment (n=91) 
EBC trial, during treatment (n=51) 
EBC trial, after treatment (n=111) 
Mean (SD) 
 
0.88 (0.13) 
0.94 (0.07) 
0.87 (0.15) 
0.96 (0.06) 
Utility-Based 
Questionnaire-Cancer 
(29 items plus single 
global health status) 
 
Algorithm to translate 
to utilities, derived in 
work on cancer 
patients via TTO 
Advanced cancer trial 
n=325, 18 or above. 
Early cancer trial 
n=126. High risk early 
state breast cancer, 
16-65 years. 
Not included because 
the method for 
deriving the utilities is 
not standard practice. 
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questions. Algorithm 
gives extra weight to 
responses about 
aspects of HRQOL 
that are more highly 
correlated with 
response on the global 
health question. 
11. 
Grunberg et 
al. (1996) 
(70) 
USA 
 
Chemotherapy with no nausea or vomiting 
Chemotherapy (3 days) with nausea or 
vomiting 
Mean 
0.79 
0.27 
VAS. Anchored from 
terrible to wonderful.  
Rating scenario of no 
PCVN and 3 vomiting 
episodes and 3 days of 
nausea. 
30 chemo patients 
(second or later 
course) mean age 56, 
22 women, 8 breast 
cancer. 15 with 
history of vomiting. 
Not included because 
states are not specific 
to breast cancer. 
 
Study suggests that 
PCNV has a severe 
impact upon HRQoL 
– it is unclear if this 
result is driven by 
those with experience 
of PCNV, those 
without experience or 
both. 
12. Hall et 
al. (1992) 
(72) 
Australia 
EBC states: 
Lumpectomy, good physical, good mental 
Mastectomy, good physical, good mental 
Lumpectomy, good physical, poor mental 
Mastectomy, good physical, poor mental 
Lumpectomy, poor physical, poor mental 
Mastectomy, poor physical, poor mental 
Mean (95% CI) 
0.80 (0.75-0.85) 
0.77 (0.71-0.83) 
 
 
0.31  
0.31  
HYE, TTO 
 
Time used in TTO 
based on respondents 
life expectancy, 
choice of 30, 20 or 10 
years. 
 
Anchored: death-full 
health. 
N=104 
44 women in the 
community, and 60 
BC patients, 
diagnosed 1-10 years 
previously, non 
recurring. 
Community sample, 
mean age 54.9 (41-
70). BC patients mean 
age 58.1 (40-70). 
Total sample, mean 
Not included because 
states are difficult to 
classify. 
 
Interpretation in Earle 
et al. (2000) is 
different. 
 
Appears to be the 
same sample as 
Gerard et al. 
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56.3 years range (40-
70). 
13. Hillner 
and Smith 
(1991) (96) 
 
USA 
Apply to the year chemotherapy is given: 
Minor toxicity with chemotherapy 
Major toxicity with chemotherapy 
First recurrence 
After first recurrence 
Second recurrence 
After second recurrence 
Third recurrence 
 
Minor toxicity defined as severe nausea and 
vomiting or weakness sufficient to require a 
reduction in activities of daily living, but not 
hospitalisation.  
Major toxicity requires hospitalisation. 
Value (range) 
0.90 (0.7-1.0) 
0.80 (0.5-0.95) 
0.70 (0.6-0.8) 
0.85 (0.7-0.9) 
0.50 (0.4-0.9) 
0.70 (0.6-0.8) 
0.30 (0.2-0.4) 
 
Not stated whether these 
are means or medians of 
values from individual 
professionals or a group 
consensus. 
Not stated, assumed to 
be based on 
judgement from dead 
(0) to well (1).  
Survey of oncologists 
and oncology nurses.  
Sample size not 
stated. 
Not included because 
sample size not given. 
14. Hillner, 
Smith and 
Desch 
(1992) (97) 
 
USA 
 
MBC states 
Chemotherapy, high dose, with complicated 
autologous bone marrow transplantation 
Chemotherapy, induction high dose 
Chemotherapy, uncomplicated high dose, with 
autologous bone marrow transplantation 
Complete remission, chemotherapy continued 
Partial remission 
Progressive disease 
Stable disease 
Standard chemotherapy 
Value (range) 
0.10 (0.05-1.0) 
 
0.50 (0.3-1.0) 
0.30 (0.1-1.0) 
 
0.85 (0.8-1.0) 
0.60 (0.5–1.0)  
0.40 (0.2-1.0) 
0.50 (0.3-1.0) 
0.70 (0.5-1.0) 
 
Not stated whether these 
are means or medians of 
values from individual 
professionals or a group 
consensus. 
VAS 
Anchored: dead - well 
Focus group of 
oncology physicians 
and nurses 
Not included because 
sample size not given, 
but since this is a 
focus group sample 
size not likely to help. 
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15. Jeruss et 
al. (2006) 
(98) 
8 clinical scenarios (see paper) Values from 0.56 to 0.89 EQ-5D Based on the 
judgement of 4 
oncologists 
Not included because 
EQ-5D scores are 
based on clinical 
judgement. 
16. Kearney 
et al. (1999) 
(52) 
ABC states: 
Start of second-line chemotherapy 
Sepsis 
Partial response (PR) 
Stable disease  (SR) 
PR and severe PN 
PR and severe peripheral oedema 
Terminal disease 
Late progressive disease 
 
 
Start of second-line chemotherapy 
Sepsis 
Partial response (PR) 
Stable disease  (SR) 
PR and severe PN 
PR and severe peripheral oedema 
Terminal disease 
Late progressive disease 
 
 
Start of second-line chemotherapy 
Sepsis 
Partial response (PR) 
Stable disease  (SR) 
PR and severe PN 
PR and severe peripheral oedema 
Terminal disease 
Late progressive disease 
 
(n=29) 
US: 0.63 (differs from 
B&H)| 
US: 0.26 (not included in 
B&H) 
US: 0.84 (as B&H) 
US: 0.70 (as B&H) 
US: 0.58 (as B&H) 
US: 0.82 (as B&H) 
US: 0.23 (as B&H) 
US: 0.49 (as B&H) 
 
(n=30) 
UK: 0.56 (differs from 
Brown 2001) 
UK: 0.16 (not inc. in 
Brown 2001) 
UK: 0.84 (as Brown 2001) 
UK: 0.70 (as Brown 2001) 
UK: 0.58 (as Brown 2001) 
UK: 0.82 (as Brown 2001) 
UK: 0.23 (as Brown 2001) 
UK: 0.49 (as Brown 2001) 
 
(n=25-30) 
IT: 0.54 GER: 0.66 SP:0.65 
IT: 0.23 GER: 0.23 SP:0.18 
IT: 0.75 GER: 0.78 SP:0.86 
IT: 0.59 GER: 0.70 SP:0.64 
IT: 0.51 GER: 0.52 SP:0.43 
SG. Anchored dead - 
perfect health. 
129 oncology nurses 
from 5 countries. 
 
Total sample, mean 
age 33.7, n=129 
Not included because 
values are reported in 
Hutton et al. (1996) 
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Start of second-line chemotherapy 
Sepsis 
Partial response (PR) 
Stable disease  (SR) 
PR and severe PN 
PR and severe peripheral oedema 
Terminal disease 
Late progressive disease 
 
 
IT: 0.69 GER: 0.73 SP:0.75 
IT: 0.19 GER: 0.14 SP:0.11 
IT: 0.50 GER: 0.39 SP:0.39 
 
AV: 0.59 
AV: 0.20 
AV: 0.81 
AV: 0.62 
AV: 0.53 
AV: 0.75 
AV: 0.16 
AV: 0.41 
17. Launois 
et al. (1997) 
(99) 
States relating to second line chemotherapy 
e.g.  terminal care 
 before staring chemotherapy 
 
0.25 
0.86 
 
Simplified version of 
the HUI 
6 independent doctors 
and nurses 
Not included because 
of limited size and 
details of sample, 
taken from CRD 
review, original 
article in French. 
18. Norum 
et al. (1997) 
(100) 
 
 
Modified radical mastectomy (MRM) 
Breast-conserving surgery (BCS) 
 
 
Anxiety and depression was reported to be a 
severe problem in 8.6–10.2% in the 
mastectomy group and 5.4–10.8% in the BCS 
group. The same figures in the slight to 
moderate problem category were 33.6–41.4% 
and 29.7–37.8%, respectively. This is assumed 
to be the only affected dimension. 
Mean 0.84 
Mean 0.87 
Assumed EQ-5D 
values from health 
states taken from 
QOL study by 
Holmberg et al.. 
(1989). 
 
 
 Not included because 
data is not original. 
19. Jansen et 
al. (2000) 
(101) 
EBC  
During chemotherapy 
 
VAS 0.77 (0.15) n=41 
TTO 0.90 (0.12) n=41 
SG 0.93 (0.10) n=38 
TTO, VAS (anchored 
at 0 dead to 1 perfect 
health) and chained 
41 EBC patients 
having adjuvant 
chemotherapy  
Not included because 
data is used elsewhere 
(Jansen et al. 2000 
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SG (25))  
20. 
Richardson 
et al. (1996) 
(102) 
EBC 
M: Mastectomy, good physical, good mental 
 
J: Mastectomy, fair physical, fair mental 
 
B: Mastectomy, poor physical, poor mental, 
relapse. 
 
W: M (5 years) & J (10 years) & B (1 year) 
Mean  
SG 0.86, TTO 0.80, VAS 
0.75 
SG 0.44, TTO 0.41, VAS 
0.48 
SG 0.19, TTO 0.16, VAS 
0.24 
 
SG 0.43, TTO 0.41, VAS 
0.46 
 
SG (n=45),  
TTO (n=47),  
VAS (n=47) 
63 female volunteers 
recruited from local 
self-help and activity 
groups and hospital 
volunteer workers. 
Average age 56.  
Not included because 
states are hard to 
classify, e.g. they 
contain how 
supportive patient’s 
husband is. 
21. Unic et 
al. (1998) 
(103) 
Netherlands 
VAS 
Prophylactic mastectomy (PM) compared to 
BC screening as preferred state. (n=47) 
 
TTO 
4 (all proven carriers) preferred PM to BCS 
47 preferred BCS of those TTO values for PM 
were (n=46) 
 
Respondents found TT0 harder than VAS. 
Authors argue this reflects the difficult of the 
decision which is obscured in VAS (page 274) 
Mean (SD) 
First session: 0.5 (0.27)  
Second session: 0.45 (0.28)  
0.77 (SD = 0.25, n = 46$ ) 
 
First session: 0.77 (0.25)  
Second session: 0.69 (0.29)   
VAS.  
Anchored: death - 
most preferred state. 
 
TTO.  
Anchored: death - 
most preferred state.  
Durations used 
changed according to 
age 
 
 
Healthy women with 
a family history of BC 
referred for screening. 
n=47 for VAS, n=46 
for TTO 
Not included because 
the anchors are not 
comparable to 
dead/full health  
 
Constant proportional 
trade-off explored and 
found significantly 
lower utilities for 
shorter durations. 
 
Test-retest for first 2 
sessions for TTO = 
0.76 and 0.96 for last 
two. 
22. 
Wittenberg 
et al. (2005) 
(104) 
USA 
Advanced cancer states, for patients with 
advanced BC or prostate cancer. 
 
Very good: Able to work full time and manage 
household, able to eat wash etc. and drive car 
Median (SD) 
 
 
ALL: 0.99 (0.11) 
PC: 0.99 (0.11) 
Chained SG.  
Anchored: worst 
health - perfect health.  
 
Using bisection 
49 patients with HR 
prostate cancer. Mean 
age 69.8 (range 45-
85) 
 
Not included because 
vignettes are difficult 
to classify. 
 
Utility values were 
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without assistance, feel well most of the time, 
have good relationships and receive strong 
support, basically a calm person and look 
forward to things. 
 
Good: Need a lot of help to work full-time or 
manage household or only work part time. 
Able to eat, wash, etc. and drive care without 
assistance, lack energy some of the time, have 
good relationships and receive strong support, 
sometimes troubled, anxious and depressed. 
 
Moderate: Not able to work in any capacity, 
able to eat, wash etc. and drive car without 
assistance, lack energy some of the time, have 
good relationships and receive strong support, 
sometimes troubled, anxious and depressed. 
 
Poor: Not able to work in any capacity, need 
assistance to eat, wash, drive, feel ill most of 
the time, have good relationships and receive 
strong support, sometimes troubled, anxious 
and depressed. 
BC: 1.0 (0.11) 
 
 
 
 
ALL: 0.85 (0.19) 
PC: 0.83 (0.16) 
BC: 0.92 (0.21) 
 
 
 
 
ALL: 0.80 (0.22) 
PC: 0.75 (0.20) 
BC: 0.91 (0.23) 
 
 
 
ALL: 0.30 (0.27) 
PC: 0.25 (0.25) 
BC: 0.30 (0.30) 
pattern.  
Rescaled to dead-
perfect health 
51 patients with 
MBC. Mean age 53.5 
(range 33-77) 
 
Total: N=100 Mean 
age 61.5 (33-85). 
found to be 
independent to 
patient’s current 
health state. 
 
Prostate cancer 
patients tend to give a 
lower value than 
breast cancer patients 
c.f. Lloyd et al. 
(2006).  
 
 
 
 
Table B.3: Studies with drug specific utility values 
 
Study Health state description Health state value How valued Who valued Comments 
1. 
Bernhard 
et al. 
(2008) 
EBC and high risk of relapse 
Baseline 
 Standard Dose-CT 
 Dose Intensive-EC 
Mean 
 
0.75 (+/-0.2) 
0.73 (+/-0.3) 
VAS (Subjective 
Health Estimations 
SHE: anchored at 
worst to best health, 
243 EBC women at 
risk of relapse from 
IBCSG trial. 
Data table refers to 
means, but text refers 
to medians. 
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(57) 
IBCSG 
Trial, 
Europe, 
Australia 
and Asia 
(also see 
values 
from Table 
B.1) 
3 months from randomisation 
 Standard Dose-CT 
 Dose Intensive-EC 
6 months from randomisation 
 Standard Dose-CT 
 Dose Intensive-EC 
9 months from randomisation 
 Standard Dose-CT 
 Dose Intensive-EC 
12 months from randomisation 
 Standard Dose-CT 
 Dose Intensive-EC 
18 months from randomisation 
 Standard Dose-CT 
 Dose Intensive-EC 
 
Toxicity: 
SD-CT: 4 courses of standard-dose 
anthracycline-based chemotherapy followed by 
3 courses of classical CMF (n=135) (months 1-
6) 
DI-EC: 3 cycles of adjuvant dose-intensive 
epirubicin and cyclophosphamide 
chemotherapy administered with filgrastim and 
progenitor cell support (n=149) (months 2-3) 
 
Time without symptoms and toxicity 
SD-CT (n=140) 
DI-EC (n=152) 
 
Relapse 
SD-CT (n=51) 
DI-EC (n=34) 
 
0.65 (+/-0.3) 
0.61 (+/-0.4) 
 
0.67 (+/-0.3) 
0.79 (+/-0.3) 
 
0.75 (+/-0.3) 
0.83 (+/-0.2) 
 
0.79 (+/-0.3) 
0.84 (+/-0.2) 
 
0.80 (+/-0.2) 
0.86 (+/-0.2) 
 
Toxicity: 
VAS: 0.60, TTO 0.77 
 
 
 
VAS: 0.57, TTO 0.74 
 
 
 
 
Time without symptoms 
VAS: 0.80, TTO 0.92 
VAS: 0.77, TTO 0.90 
 
Relapse 
VAS: 0.80, TTO 0.92 
VAS: 0.77, TTO 0.90 
patients asked to 
imagine spending the 
rest of their life in 
their current health 
state, then to value it). 
 
SHE converted to 
TTO in study 
described above. 
 
 
2. Metatstatic bone disease: ABC Mean (95% CI) healthy TTO. Healthy months 25 Canadian women  
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Dranitsaris 
et al. 
(1999) 
(53) 
Canada 
 
 
SRE with pamidronate  
 
No SRE with pamidronate 
 
SRE with placebo 
 
No SRE with placebo 
 
months equivalent 
Public 5.46 (4.39-6.53)  
Staff 4.80 (3.39–5.63) 
Public 7.73 (6.30-9.16) 
Staff 9.92 (9.24-10.60) 
Public 3.68 (2.75-4.61) 
Staff 4.13 (3.36–4.90) 
Public 6.76 (5.39-8.13) 
Staff 7.89 (6.87–8.92) 
equivalent. 12 months 
in health state. 
Anchored at dead to 
perfect health.  
 
No option of state 
worse than dead. 
 
living in Ontario 
(>=18yrs). Median 
age 45 (range 22-66) 
 
And 25 female health 
care professionals 
with experience in 
oncology. Median age 
40, range 26–56). 
3. 
Dranitsaris 
et al. 
(2000) 
(54) 
Canada 
Second-line hormonal therapy in ABC: 
 
Letrozole: 
No response and progression during 
chemotherapy: FAC (5-FU, doxorubicin and 
cyclophosphamide) 
 
No response to letrozole but response to FAC 
 
Response to letrozole 
 
 
Anastrozole: 
No response and progression during FAC 
 
No response to anatrozole but response to FAC 
 
Response to anatrozole 
 
MA (Megestrol acetate) 
No response and progression during FAC 
 
No response to MA but response to FAC 
 
Response to MA 
Mean (95% CI) 
 
 
Pub: 0.45 (0.37-0.55) 
Staff: 0.53 (0.45-0.92) 
 
 
Pub: 0.67 (0.55-0.79) 
Staff: 0.57 (0.49-0.65) 
Pub: 0.80 (0.49-0.73) [error 
in original] 
Staff: 0.78 (0.71-0.84) 
 
Pub: 0.45 (0.37-0.55) 
Staff: 0.53 (0.45-0.92) 
Pub: 0.67 (0.55-0.79) 
Staff: 0.57 (0.49-0.65) 
Pub: 0.80 (0.70-0.92) 
Staff: 0.72 (0.66-0.78) 
 
Pub: 0.45 (0.35-0.55) 
Staff: 0.40 (0.30-0.48) 
Pub: 0.64 (0.52-0.76) 
Staff: 0.53 (0.44-0.61) 
Pub: 0.80 (0.69-0.91) 
TTO. Quality adjusted 
progression free 
periods were 
measures as ‘Healthy 
month equivalent’ for 
time in each outcome. 
Rescaled to be 
anchored at death and 
perfect health.  
 
25 Canadian women 
living in Ontario 
(>=18years). 
Median age was 50.5 
(range 20-81), 36% 
received post 
secondary education, 
8% had received some 
form of cancer 
therapy in the past. 
 
Also 25 health care 
workers, median age 
37 (range 22-61), 96% 
received post 
secondary education, 
0% had received 
cancer therapy. 
The paper notes that 
due to an absence of 
data from head-to-
head comparison 
between letrozole and 
anastrozole and 
identical side effect 
profile was assumed. 
Differences in 
valuations in 
responses to letrozole 
and anastrozole must 
derive from future 
expectations. 
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Staff: 0.67 (0.58-0.76)  
4. 
Fountzilas 
et al. 
(2009) 
(105) 
 
Greece 
MBC: 
Paclitaxel and carboplatin every 3 wks (PCb) 
 Pre (n=100) 
 Post (n=78) 
 6 month follow-up (n=74) 
 
 Pre (n=100) 
 Post (n=79) 
 6 month follow-up (n=74) 
 
Docetaxel & gemcitabine every 3 wks (GDoc) 
 Pre (n=100) 
 Post (n=73) 
 6 month follow-up (n=62) 
 
 Pre (n=97) 
 Post (n=73) 
 6 month follow-up (n=61) 
 
Paclitaxel weekly (Pw) 
 Pre (n=100) 
 Post (n=73) 
 6 month follow-up (n=62) 
 
 Pre (n=97) 
 Post (n=73) 
 6 month follow-up (n=61) 
Mean (SD), Median 
 
EQ-5D: 0.62 (0.26), 0.69 
EQ-5D: 0.68 (0.22), 0.70 
EQ-5D: 0.70 (0.27), 0.78 
 
VAS: 0.66 (0.21), 0.70 
VAS: 0.70 (0.16), 0.70 
VAS: 0.73 (0.19), 0.75 
 
 
EQ-5D: 0.59 (0.25), 0.66 
EQ-5D: 0.65 (0.21), 0.69 
EQ-5D: 0.69 (0.23), 0.76 
 
VAS: 0.67 (0.20), 0.70 
VAS: 0.70 (0.16), 0.70 
VAS: 0.61 (0.17), 0.80 
 
 
EQ-5D: 0.63 (0.24), 0.69 
EQ-5D: 0.66 (0.25), 0.69 
EQ-5D: 0.74 (0.22), 0.78 
 
VAS: 0.72 (0.19), 0.70 
VAS: 0.73 (0.18), 0.75 
VAS: 0.81 (0.14), 0.80 
EQ-5D, European 
tariff. 
Inclusion: Patients 
with histologically 
proven MBC, life 
expectancy >= 12 
weeks, age >=18. 
 
Age: PCb (n=136) 
median 60; GDoc 
(n=144) median 60; 
Pw (n=136) median 
60.5 
 
5. Leung et 
al. (1999) 
(55) 
Canada 
MBC states: 
Paclitaxel: Toxicity from treatment 
     Response to treatment 
     No response to treatment 
Docetaxel: Toxicity from treatment 
Mean (Healthy volunteers, 
Patients) 
0.12 HV, 0.11 PAT 
0.62 HV, 0.61 PAT 
0.24 HV, 0.26 PAT 
TTO. 4 months 
treatment v months in 
perfect health. 
 
25 healthy, oncology 
care providers. 
Median age 34 (range 
23-55) 
 
No significant 
differences between 
patients and healthy 
volunteers 
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     Response to treatment 
     No response to treatment 
Vinorelbine: Toxicity from treatment 
        Response to treatment  
        No response to treatment 
0.10 HV, 0.09 PAT 
0.51 HV, 0.49 PAT 
0.17 HV, 0.17 PAT 
0.23 HV, 0.16 PAT 
0.80 HV, 0.77 PAT 
0.41 HV, 0.33 PAT 
25 patients (11 
metastatic, others 
stage I/II). Median 
age 55 (range 31-73) 
 
 
Table B.4: Studies for which utility values could not be presented 
 
Study Comment  
1. Chie et al. (2000) (106) 
Taiwan 
Utility values from 21 experts in Taiwan using VAS, TTO and SG for 17 BC states. Most data is presented graphically. Three rounds of 
interviews were used, and experts were presented with median values, scores converged to median values for most phases in the second 
and third rounds. SG and TTO values were higher than VAS, except for terminal/hospice stage. Utility values which are reported are  
VAS (anchored at dead-perfect health) values reported for screening phase (100 or 90), finding of a tumour (75), diagnosis (70), 
adjuvant chemotherapy (50), BCS (65), MRM (60), recurrence or metastasis (30), terminal stage in general ward (10), terminal at home 
or hospice (12.5). TTO and SG values are reported for diagnosis phase (90). 
2. Franic and Pathak (2003) 
(75) 
Study considers the impact of excluding values worse than dead. A sample of women (n=119, without experience of BC) valued 3 
states: cure, treatment and recurrence. Utility values are only presented as differences between states. 
3. Hayman et al. (2001) 
Abstract only. 
SG utility values for combinations of treatment (BCS and radiotherapy) from a group of 120 women with a history of DCIS and 97 
women with a history of stage I/II BC. Utility values are presented only as differences. 
4. Hwang and Wang (2004) 
(107) Thailand 
Cross-sectional survey on 223 BC patients using SG and the questionnaire WHOQOL-100 rescaled to 0-1. 64, 72, 69 and 28 patients in 
stages I–IV, respectively. Only quality-adjusted survival time (QAST) shown.  
5. Kestle et al. (1989) (108) 
Canada 
Abstract only 
Data from an RCT comparing 12 and 36 weeks of adjuvant chemotherapy. Uses TTO anchored at death and good health. Utility values 
are only presented as changes. 
6. Perez et al. (2001) (77) 
New Zealand 
Study includes 54 patients presenting at Dunedin Hospital, New Zealand, with metastatic cancer. 5 refused to complete the TTO task 
due to moral, philosophical or other reasons. 21 died during the study, 9 withdraw due to poor health. Mean age 58.7, 50% had been 
diagnosed for more than 1 year. Respondents asked to trade off days in the forthcoming month to change current health status (assumed 
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the same as last month). TTO exercise completed monthly for 12 months (13 datasets). Also completed Spitzer QoL uniscale (5 VAS 
from 0-2, added together). In most time periods over 2/3rds of women did not trade any days (14 did not trade on any occasion.). Data 
not reported in an appropriate format. 
7. Polsky et al. (2003) (77) 
USA 
Considers the impact of patient choice on health state preferences following mastectomy and BCSRT. Assessed 3-5 years after surgery 
on 1,320 of the surviving subjects, using EQ-VAS. Values only shown graphically. 
8. Stalmeier et al. (1996) 
(109) 
Studies investigating preference reversal in TTO valuations using values for MBC state. Valuations are from students without BC. Data 
is not presented in a usable format.  
9. Suh et al. (2003) (110) 
Abstract only. 
Abstract refers to data from a study collecting utility values for 8 non-metastatic health states from n=210 healthy women and n=112 
women with DCIS. No other details available. 
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